diseaseId	diseaseName	drugId	drugName	type	mechanismOfAction	actionType	symbol	name	phase	status	source
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	4	Completed	https://clinicaltrials.gov/study/NCT01041040,https://clinicaltrials.gov/study/NCT00304447
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	4		https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06370000
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06370000
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4	Completed	https://clinicaltrials.gov/study/NCT00487448,https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00180115
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4	Completed	https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00487448,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00180115
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4	Completed	https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00487448,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00488709
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4	Completed	https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00487448
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4	Completed	https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00487448
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4	Completed	https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00487448
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02277847
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02024308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT02926586
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4	Unknown status	https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT00199147
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT01587430
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02277847
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4	Unknown status	https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02024308
EFO_0000222	acute myeloid leukemia	CHEMBL1200976	IDARUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d521b65f-3fd2-4efe-8cab-b444921dd223
EFO_0000222	acute myeloid leukemia	CHEMBL1200976	IDARUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4	Unknown status	https://clinicaltrials.gov/study/NCT02277847
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4	Completed	https://clinicaltrials.gov/study/NCT00180167
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	4		https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103362s5237lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha 	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103362s5237lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/xospata
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/xospata
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	4		https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL4297610	OLUTASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL3989931	ENASIDENIB MESYLATE	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL4297534	GLASDEGIB MALEATE	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=204a6f7e-c9a4-472b-abd2-9527bda64d17,https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03026842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4	Completed	https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00487448,https://clinicaltrials.gov/study/NCT00488709
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4	Completed	https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00487448,https://clinicaltrials.gov/study/NCT00180115
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4	Completed	https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00180167,https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00487448
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4	Completed	https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00487448,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00180167
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4	Completed	https://clinicaltrials.gov/study/NCT00488709,https://clinicaltrials.gov/study/NCT00487448,https://clinicaltrials.gov/study/NCT00180102,https://clinicaltrials.gov/study/NCT00180115,https://clinicaltrials.gov/study/NCT00464217,https://clinicaltrials.gov/study/NCT00180167
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4	Terminated	https://clinicaltrials.gov/study/NCT03988205
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT02926586
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02277847
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT02024308,https://clinicaltrials.gov/study/NCT01587430
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4	Unknown status	https://clinicaltrials.gov/study/NCT00199147,https://clinicaltrials.gov/study/NCT01587430,https://clinicaltrials.gov/study/NCT02277847,https://clinicaltrials.gov/study/NCT02926586,https://clinicaltrials.gov/study/NCT02024308
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT02039726
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT04087967
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT01484171
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Completed	https://clinicaltrials.gov/study/NCT02668653,https://clinicaltrials.gov/study/NCT02039726
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	3	Completed	https://clinicaltrials.gov/study/NCT02668653,https://clinicaltrials.gov/study/NCT02039726
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Withdrawn	https://clinicaltrials.gov/study/NCT04676243
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Withdrawn	https://clinicaltrials.gov/study/NCT04676243
EFO_0000222	acute myeloid leukemia	CHEMBL578	ENALAPRIL	Small molecule	Angiotensin-converting enzyme inhibitor		ACE	angiotensin I converting enzyme	3	Completed	https://clinicaltrials.gov/study/NCT01110824
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03926624
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01828489
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1201081	METHYLPREDNISOLONE SODIUM SUCCINATE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Terminated	https://clinicaltrials.gov/study/NCT00568633
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02172872,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT04229979
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Completed	https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT03941964,https://clinicaltrials.gov/study/NCT01303796,https://clinicaltrials.gov/study/NCT03306264
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Completed	https://clinicaltrials.gov/study/NCT03306264,https://clinicaltrials.gov/study/NCT01303796,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT03941964
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06297772,https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Unknown status	https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01633099
EFO_0000222	acute myeloid leukemia	CHEMBL1201132	NALBUPHINE HYDROCHLORIDE	Small molecule	Opioid receptors; mu/kappa/delta agonist		OPRM1	opioid receptor mu 1	3	Completed	https://clinicaltrials.gov/study/NCT03825887
EFO_0000222	acute myeloid leukemia	CHEMBL1201132	NALBUPHINE HYDROCHLORIDE	Small molecule	Opioid receptors; mu/kappa/delta agonist		OPRD1	opioid receptor delta 1	3	Completed	https://clinicaltrials.gov/study/NCT03825887
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	3	Completed	https://clinicaltrials.gov/study/NCT00006363
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT00006363
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	3	Recruiting	https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT04168502
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00820976,https://clinicaltrials.gov/study/NCT02039726
EFO_0000222	acute myeloid leukemia	CHEMBL635	PREDNISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04229979
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Completed	https://clinicaltrials.gov/study/NCT01191801
EFO_0000222	acute myeloid leukemia	CHEMBL70	MORPHINE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	3	Completed	https://clinicaltrials.gov/study/NCT03825887
EFO_0000222	acute myeloid leukemia	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB1	adrenoceptor beta 1	3	Completed	https://clinicaltrials.gov/study/NCT01110824
EFO_0000222	acute myeloid leukemia	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1A	adrenoceptor alpha 1A	3	Completed	https://clinicaltrials.gov/study/NCT01110824
EFO_0000222	acute myeloid leukemia	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1B	adrenoceptor alpha 1B	3	Completed	https://clinicaltrials.gov/study/NCT01110824
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04090736
EFO_0000222	acute myeloid leukemia	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1D	adrenoceptor alpha 1D	3	Completed	https://clinicaltrials.gov/study/NCT01110824
EFO_0000222	acute myeloid leukemia	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00186966
EFO_0000222	acute myeloid leukemia	CHEMBL1233528	VOLASERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	3	Completed	https://clinicaltrials.gov/study/NCT01721876
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT02072811
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1425	MERCAPTOPURINE ANHYDROUS	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	3	Completed	https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00962767
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Completed	https://clinicaltrials.gov/study/NCT00075478,https://clinicaltrials.gov/study/NCT00412360,https://clinicaltrials.gov/study/NCT02461121
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT00075478,https://clinicaltrials.gov/study/NCT00412360,https://clinicaltrials.gov/study/NCT02461121
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Terminated	https://clinicaltrials.gov/study/NCT00568633
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Unknown status	https://clinicaltrials.gov/study/NCT01766375
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04161885,https://clinicaltrials.gov/study/NCT04090736,https://clinicaltrials.gov/study/NCT01757535,https://clinicaltrials.gov/study/NCT03173248,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT02421939
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01757535,https://clinicaltrials.gov/study/NCT04161885,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04090736,https://clinicaltrials.gov/study/NCT03173248,https://clinicaltrials.gov/study/NCT04229979
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Completed	https://clinicaltrials.gov/study/NCT00887068,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT05188326,https://clinicaltrials.gov/study/NCT01074047,https://clinicaltrials.gov/study/NCT03941964
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05264883,https://clinicaltrials.gov/study/NCT05907057,https://clinicaltrials.gov/study/NCT05654194,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT04490707,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT05183035
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT05654194,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT04490707,https://clinicaltrials.gov/study/NCT05264883,https://clinicaltrials.gov/study/NCT05907057
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT01802333
EFO_0000222	acute myeloid leukemia	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	3	Completed	https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT00075478,https://clinicaltrials.gov/study/NCT00412360
EFO_0000222	acute myeloid leukemia	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT03182244
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT02421939
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00480064
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT04509622
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT00151255
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT06345365
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03897127
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT04083911
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Terminated	https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT02298166,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT00513305
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT02298166,https://clinicaltrials.gov/study/NCT02545283
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Terminated	https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT02298166,https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT02545283
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Terminated	https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Terminated	https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT01615757,https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT01145846
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01615757
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT01615757,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT02985372
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01615757
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT01615757,https://clinicaltrials.gov/study/NCT02072811
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT01615757,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT02985372
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01615757
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Unknown status	https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT01615757,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT02985372
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL1086218	VALSPODAR	Protein	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	3	Completed	https://clinicaltrials.gov/study/NCT00006363
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00075478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04490707
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	3	Recruiting	https://clinicaltrials.gov/study/NCT04490707
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04490707
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT02421939
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT00363025
EFO_0000222	acute myeloid leukemia	CHEMBL895	NALBUPHINE	Small molecule	Opioid receptors; mu/kappa/delta agonist		OPRK1	opioid receptor kappa 1	3	Completed	https://clinicaltrials.gov/study/NCT03825887
EFO_0000222	acute myeloid leukemia	CHEMBL895	NALBUPHINE	Small molecule	Opioid receptors; mu/kappa/delta agonist		OPRM1	opioid receptor mu 1	3	Completed	https://clinicaltrials.gov/study/NCT03825887
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00703820
EFO_0000222	acute myeloid leukemia	CHEMBL895	NALBUPHINE	Small molecule	Opioid receptors; mu/kappa/delta agonist		OPRD1	opioid receptor delta 1	3	Completed	https://clinicaltrials.gov/study/NCT03825887
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00703820
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1200751	MERCAPTOPURINE	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	3	Completed	https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00962767
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02172872,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT05177731
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730,https://clinicaltrials.gov/study/NCT06297772
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	3	Completed	https://clinicaltrials.gov/study/NCT01802333
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05382390,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT05264883
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	3	Completed	https://clinicaltrials.gov/study/NCT01802333
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT05382390,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT05264883,https://clinicaltrials.gov/study/NCT05586074
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT01382147,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00589082,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT02140242,https://clinicaltrials.gov/study/NCT00474006
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Terminated	https://clinicaltrials.gov/study/NCT02785900
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Terminated	https://clinicaltrials.gov/study/NCT02785900
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT01633099,https://clinicaltrials.gov/study/NCT02985372
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT00363025
EFO_0000222	acute myeloid leukemia	CHEMBL1201132	NALBUPHINE HYDROCHLORIDE	Small molecule	Opioid receptors; mu/kappa/delta agonist		OPRK1	opioid receptor kappa 1	3	Completed	https://clinicaltrials.gov/study/NCT03825887
EFO_0000222	acute myeloid leukemia	CHEMBL1201265	METHYLPREDNISOLONE HEMISUCCINATE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Terminated	https://clinicaltrials.gov/study/NCT00568633
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	3	Completed	https://clinicaltrials.gov/study/NCT00476541,https://clinicaltrials.gov/study/NCT00962767,https://clinicaltrials.gov/study/NCT00893399,https://clinicaltrials.gov/study/NCT00860639
EFO_0000222	acute myeloid leukemia	CHEMBL1201565	EPOETIN ALFA	Protein	Erythropoietin receptor agonist		EPOR	erythropoietin receptor	3	Completed	https://clinicaltrials.gov/study/NCT00656448
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03182244
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03250338
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Terminated	https://clinicaltrials.gov/study/NCT03504410
EFO_0000222	acute myeloid leukemia	CHEMBL1201587	ALEMTUZUMAB	Antibody	CAMPATH-1 antigen inhibitor		CD52	CD52 molecule	3	Withdrawn	https://clinicaltrials.gov/study/NCT00226512
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha 	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04229979
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04090736
EFO_0000222	acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT04168502
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Recruiting	https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Terminated	https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	3	Terminated	https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL2108342	GEMTUZUMAB	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT02039726
EFO_0000222	acute myeloid leukemia	CHEMBL2108811	VISILIZUMAB	Antibody	T-cell surface glycoprotein CD3 epsilon chain inhibitor		CD3E	CD3 epsilon subunit of T-cell receptor complex	3	Recruiting	https://clinicaltrials.gov/study/NCT04722952
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	3	Completed	https://clinicaltrials.gov/study/NCT00093990
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Terminated	https://clinicaltrials.gov/study/NCT00568633
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Unknown status	https://clinicaltrials.gov/study/NCT01766375
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	3	Recruiting	https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT05654194,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT05264883
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	3	Terminated	https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT05079230
EFO_0000222	acute myeloid leukemia	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Completed	https://clinicaltrials.gov/study/NCT02997202
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Completed	https://clinicaltrials.gov/study/NCT01074047,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT03941964,https://clinicaltrials.gov/study/NCT05188326,https://clinicaltrials.gov/study/NCT00887068
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730,https://clinicaltrials.gov/study/NCT06389292
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730,https://clinicaltrials.gov/study/NCT06389292
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Terminated	https://clinicaltrials.gov/study/NCT03151408,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT02785900,https://clinicaltrials.gov/study/NCT05079230
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Terminated	https://clinicaltrials.gov/study/NCT02785900,https://clinicaltrials.gov/study/NCT05079230,https://clinicaltrials.gov/study/NCT03151408,https://clinicaltrials.gov/study/NCT04778397
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Recruiting	https://clinicaltrials.gov/study/NCT04314219
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Unknown status	https://clinicaltrials.gov/study/NCT01766375
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT04716114
EFO_0000222	acute myeloid leukemia	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	3	Terminated	https://clinicaltrials.gov/study/NCT00568633
EFO_0000222	acute myeloid leukemia	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	3	Unknown status	https://clinicaltrials.gov/study/NCT01766375
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	3	Completed	https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00962767,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00146120
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	3	Recruiting	https://clinicaltrials.gov/study/NCT05654194
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	3	Recruiting	https://clinicaltrials.gov/study/NCT05654194
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL3833386	GALINPEPIMUT-S	Cell	Wilms tumor protein vaccine antigen		WT1	WT1 transcription factor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04229979
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Recruiting	https://clinicaltrials.gov/study/NCT03765541
EFO_0000222	acute myeloid leukemia	CHEMBL3989971	UPROLESELAN	Small molecule	Selectin E antagonist		SELE	selectin E	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616470
EFO_0000222	acute myeloid leukemia	CHEMBL3989971	UPROLESELAN	Small molecule	Selectin E antagonist		SELE	selectin E	3	Recruiting	https://clinicaltrials.gov/study/NCT05054543
EFO_0000222	acute myeloid leukemia	CHEMBL2109128	LENOGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT02319135
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00006363
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Recruiting	https://clinicaltrials.gov/study/NCT03926624
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Terminated	https://clinicaltrials.gov/study/NCT03504410
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT03504410
EFO_0000222	acute myeloid leukemia	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	3	Terminated	https://clinicaltrials.gov/study/NCT02545283
EFO_0000222	acute myeloid leukemia	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	3	Terminated	https://clinicaltrials.gov/study/NCT02545283
EFO_0000222	acute myeloid leukemia	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT00093990
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT04161885,https://clinicaltrials.gov/study/NCT05177731
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	3	Completed	https://clinicaltrials.gov/study/NCT03941964,https://clinicaltrials.gov/study/NCT04509622
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06073730
EFO_0000222	acute myeloid leukemia	CHEMBL3265032	ENTOSPLETINIB	Small molecule	Tyrosine-protein kinase SYK inhibitor		SYK	spleen associated tyrosine kinase	3	Terminated	https://clinicaltrials.gov/study/NCT05020665
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT05177731
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02997202
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Completed	https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00962767
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Terminated	https://clinicaltrials.gov/study/NCT01749111
EFO_0000222	acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05726110
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	3	Recruiting	https://clinicaltrials.gov/study/NCT04716114
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Recruiting	https://clinicaltrials.gov/study/NCT04716114
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	3	Completed	https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00962767,https://clinicaltrials.gov/study/NCT00151255
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	3	Completed	https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00962767,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00151255
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05654194
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00703820
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00703820
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00317642
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL389621	HYDROCORTISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05477589
EFO_0000222	acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03173248
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT03897127
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01828489
EFO_0000222	acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	3	Completed	https://clinicaltrials.gov/study/NCT03416179
EFO_0000222	acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	3	Terminated	https://clinicaltrials.gov/study/NCT04093505
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT03250338
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Terminated	https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL4297985	MAGROLIMAB	Antibody	Leukocyte surface antigen CD47 inhibitor		CD47	CD47 molecule	3	Terminated	https://clinicaltrials.gov/study/NCT05079230,https://clinicaltrials.gov/study/NCT04778397
EFO_0000222	acute myeloid leukemia	CHEMBL43	AMSACRINE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Recruiting	https://clinicaltrials.gov/study/NCT03765541
EFO_0000222	acute myeloid leukemia	CHEMBL43	AMSACRINE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT03765541
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT02421939
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT03182244
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00880243
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT03926624
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1086218	VALSPODAR	Protein	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	3	Completed	https://clinicaltrials.gov/study/NCT00006363
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Completed	https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT02668653
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	3	Completed	https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT02668653
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT02668653
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	3	Completed	https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT02668653
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Withdrawn	https://clinicaltrials.gov/study/NCT04676243
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	3	Withdrawn	https://clinicaltrials.gov/study/NCT04676243
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	3	Withdrawn	https://clinicaltrials.gov/study/NCT04676243
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	3	Withdrawn	https://clinicaltrials.gov/study/NCT04676243
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT01382147,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00136084
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00322101,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Completed	https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_0000330	childhood acute myeloid leukemia	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	3	Completed	https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL389621	HYDROCORTISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00369317
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	3	Completed	https://clinicaltrials.gov/study/NCT03512197,https://clinicaltrials.gov/study/NCT03379727
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	3	Completed	https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03512197
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	3	Recruiting	https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT01191801
EFO_0000222	acute myeloid leukemia	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB2	adrenoceptor beta 2	3	Completed	https://clinicaltrials.gov/study/NCT01110824
EFO_0000222	acute myeloid leukemia	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB3	adrenoceptor beta 3	3	Completed	https://clinicaltrials.gov/study/NCT01110824
EFO_0000222	acute myeloid leukemia	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Completed	https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00186966
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT02421939
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT03182244
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT04293562,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT01371981
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03182244,https://clinicaltrials.gov/study/NCT02421939,https://clinicaltrials.gov/study/NCT04229979,https://clinicaltrials.gov/study/NCT01371981,https://clinicaltrials.gov/study/NCT05177731,https://clinicaltrials.gov/study/NCT04293562
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT00266136
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00428558
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT00151255
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00260832
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT02013648,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00474006
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT01721876,https://clinicaltrials.gov/study/NCT03379727,https://clinicaltrials.gov/study/NCT00428558,https://clinicaltrials.gov/study/NCT00151255,https://clinicaltrials.gov/study/NCT00317642,https://clinicaltrials.gov/study/NCT00474006,https://clinicaltrials.gov/study/NCT01497002,https://clinicaltrials.gov/study/NCT00136084,https://clinicaltrials.gov/study/NCT01696084,https://clinicaltrials.gov/study/NCT03416179,https://clinicaltrials.gov/study/NCT02461121,https://clinicaltrials.gov/study/NCT00186966,https://clinicaltrials.gov/study/NCT01191801,https://clinicaltrials.gov/study/NCT00703820,https://clinicaltrials.gov/study/NCT02319135,https://clinicaltrials.gov/study/NCT02461537,https://clinicaltrials.gov/study/NCT02039726,https://clinicaltrials.gov/study/NCT00480064,https://clinicaltrials.gov/study/NCT04509622,https://clinicaltrials.gov/study/NCT00266136,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT01237808,https://clinicaltrials.gov/study/NCT00495287,https://clinicaltrials.gov/study/NCT01802333,https://clinicaltrials.gov/study/NCT00931138,https://clinicaltrials.gov/study/NCT00927498,https://clinicaltrials.gov/study/NCT00260832,https://clinicaltrials.gov/study/NCT00146120,https://clinicaltrials.gov/study/NCT00880243,https://clinicaltrials.gov/study/NCT02013648
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03507842
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06182592
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT03384212
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT03897127
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT03765541
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Recruiting	https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT05183035
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT03384225,https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT03897127
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT03250338,https://clinicaltrials.gov/study/NCT02724163,https://clinicaltrials.gov/study/NCT04087967,https://clinicaltrials.gov/study/NCT04083911,https://clinicaltrials.gov/study/NCT03257241,https://clinicaltrials.gov/study/NCT03897127,https://clinicaltrials.gov/study/NCT03765541,https://clinicaltrials.gov/study/NCT06345365,https://clinicaltrials.gov/study/NCT05183035,https://clinicaltrials.gov/study/NCT05586074,https://clinicaltrials.gov/study/NCT04174612,https://clinicaltrials.gov/study/NCT03258931,https://clinicaltrials.gov/study/NCT03021330,https://clinicaltrials.gov/study/NCT03926624,https://clinicaltrials.gov/study/NCT03384212,https://clinicaltrials.gov/study/NCT05726110,https://clinicaltrials.gov/study/NCT03384225
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT02298166,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT00513305
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT02298166,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT03504410
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT02298166,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT00513305
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT01246752,https://clinicaltrials.gov/study/NCT02298166
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Terminated	https://clinicaltrials.gov/study/NCT00513305,https://clinicaltrials.gov/study/NCT04778397,https://clinicaltrials.gov/study/NCT05020665,https://clinicaltrials.gov/study/NCT02298166,https://clinicaltrials.gov/study/NCT02545283,https://clinicaltrials.gov/study/NCT03504410,https://clinicaltrials.gov/study/NCT01246752
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT01615757
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Unknown status	https://clinicaltrials.gov/study/NCT01615757,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT02072811,https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01414231
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT01414231,https://clinicaltrials.gov/study/NCT02985372,https://clinicaltrials.gov/study/NCT01615757,https://clinicaltrials.gov/study/NCT01145846,https://clinicaltrials.gov/study/NCT02072811
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Withdrawn	https://clinicaltrials.gov/study/NCT01067274
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	3	Recruiting	https://clinicaltrials.gov/study/NCT04490707
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00322101
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00322101
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00136084
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	3	Completed	https://clinicaltrials.gov/study/NCT01802333
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	3	Completed	https://clinicaltrials.gov/study/NCT01802333
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02993523,https://clinicaltrials.gov/study/NCT02752035
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02993523,https://clinicaltrials.gov/study/NCT02752035
EFO_0000330	childhood acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_0000330	childhood acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Completed	https://clinicaltrials.gov/study/NCT00322101
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02993523
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02752035
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02752035
EFO_0000330	childhood acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Completed	https://clinicaltrials.gov/study/NCT00322101,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363
EFO_0000330	childhood acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00369317
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL389621	HYDROCORTISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00006363
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1086218	VALSPODAR	Protein	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	3	Completed	https://clinicaltrials.gov/study/NCT00006363
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00369317
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00002798,https://clinicaltrials.gov/study/NCT00006363,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00085124
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL2109229	OBLIMERSEN SODIUM	Oligonucleotide	Bcl-2 mRNA antisense inhibitor		BCL2	BCL2 apoptosis regulator	3	Completed	https://clinicaltrials.gov/study/NCT00085124
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Completed	https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00085124
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00085124
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Completed	https://clinicaltrials.gov/study/NCT00322101
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	3	Completed	https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL727	THIOGUANINE	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00085124
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00369317,https://clinicaltrials.gov/study/NCT00085124
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00085124,https://clinicaltrials.gov/study/NCT00369317
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00715637
EFO_0000222	acute myeloid leukemia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRG	retinoid X receptor gamma	2	Terminated	https://clinicaltrials.gov/study/NCT00615784
EFO_0000222	acute myeloid leukemia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRB	retinoid X receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00615784
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL109	VALPROIC ACID	Small molecule	Succinate semialdehyde dehydrogenase inhibitor		ALDH5A1	aldehyde dehydrogenase 5 family member A1	2	Unknown status	https://clinicaltrials.gov/study/NCT02124174
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL5095030	MOTIXAFORTIDE	Protein	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	2	Completed	https://clinicaltrials.gov/study/NCT02639559,https://clinicaltrials.gov/study/NCT01838395
EFO_0000222	acute myeloid leukemia	CHEMBL5095030	MOTIXAFORTIDE	Protein	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02502968
EFO_0000222	acute myeloid leukemia	CHEMBL513909	BI-2536	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00701766
EFO_0000222	acute myeloid leukemia	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03953898
EFO_0000222	acute myeloid leukemia	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03953898
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01736943
EFO_0000222	acute myeloid leukemia	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT03059615
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT03128359
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT03128359
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04107727
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04107727
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04107727
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT02984995,https://clinicaltrials.gov/study/NCT01565668,https://clinicaltrials.gov/study/NCT00989261
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT02984995,https://clinicaltrials.gov/study/NCT01565668,https://clinicaltrials.gov/study/NCT00989261
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00989261,https://clinicaltrials.gov/study/NCT01565668,https://clinicaltrials.gov/study/NCT02984995
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01565668,https://clinicaltrials.gov/study/NCT00989261,https://clinicaltrials.gov/study/NCT02984995
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT01565668,https://clinicaltrials.gov/study/NCT02984995,https://clinicaltrials.gov/study/NCT00989261
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT04209725
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT04968015
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT04209725
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT04209725
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT02096055,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT01035502,https://clinicaltrials.gov/study/NCT02671708,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT01700413,https://clinicaltrials.gov/study/NCT01015196,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT00067028
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT04209725
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT00967512
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT03135054
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT03135054
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT03135054
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Unknown status	https://clinicaltrials.gov/study/NCT03135054
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05285813
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Anandamide amidohydrolase inhibitor		FAAH	fatty acid amide hydrolase	2	Recruiting	https://clinicaltrials.gov/study/NCT05285813
EFO_0000222	acute myeloid leukemia	CHEMBL1171837	PONATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03690115,https://clinicaltrials.gov/study/NCT04188405
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Suspended	https://clinicaltrials.gov/study/NCT02462265
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL601719	CRIZOTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL601719	CRIZOTINIB	Small molecule	EML4-ALK		EML4	EMAP like 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL601719	CRIZOTINIB	Small molecule	NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)		NPM1	nucleophosmin 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL603469	LESTAURTINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00079482
EFO_0000222	acute myeloid leukemia	CHEMBL603469	LESTAURTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00079482
EFO_0000222	acute myeloid leukemia	CHEMBL603469	LESTAURTINIB	Small molecule	NT-3 growth factor receptor inhibitor		NTRK3	neurotrophic receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00079482
EFO_0000222	acute myeloid leukemia	CHEMBL603469	LESTAURTINIB	Small molecule	Neurotrophic tyrosine kinase receptor type 2 inhibitor		NTRK2	neurotrophic receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00079482
EFO_0000222	acute myeloid leukemia	CHEMBL603469	LESTAURTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00079482
EFO_0000222	acute myeloid leukemia	CHEMBL603469	LESTAURTINIB	Small molecule	Nerve growth factor receptor Trk-A inhibitor		NTRK1	neurotrophic receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00079482
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04188405,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT04975919
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04975919,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT04188405
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Completed	https://clinicaltrials.gov/study/NCT00398983,https://clinicaltrials.gov/study/NCT00867672,https://clinicaltrials.gov/study/NCT02073838,https://clinicaltrials.gov/study/NCT01420926,https://clinicaltrials.gov/study/NCT00358644,https://clinicaltrials.gov/study/NCT04476199,https://clinicaltrials.gov/study/NCT00414310,https://clinicaltrials.gov/study/NCT00866073,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00760084,https://clinicaltrials.gov/study/NCT00882102,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT02252107,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT02472145,https://clinicaltrials.gov/study/NCT00968071,https://clinicaltrials.gov/study/NCT01687400
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Completed	https://clinicaltrials.gov/study/NCT00398983,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT02472145,https://clinicaltrials.gov/study/NCT00414310,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00866073,https://clinicaltrials.gov/study/NCT02073838,https://clinicaltrials.gov/study/NCT04476199,https://clinicaltrials.gov/study/NCT01420926,https://clinicaltrials.gov/study/NCT00882102,https://clinicaltrials.gov/study/NCT02252107,https://clinicaltrials.gov/study/NCT00358644,https://clinicaltrials.gov/study/NCT00968071,https://clinicaltrials.gov/study/NCT00760084,https://clinicaltrials.gov/study/NCT01687400,https://clinicaltrials.gov/study/NCT00867672,https://clinicaltrials.gov/study/NCT01829503
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04353479
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05184842,https://clinicaltrials.gov/study/NCT04763928,https://clinicaltrials.gov/study/NCT04746235,https://clinicaltrials.gov/study/NCT04752527,https://clinicaltrials.gov/study/NCT04905810,https://clinicaltrials.gov/study/NCT02781883,https://clinicaltrials.gov/study/NCT05799079,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT06379360,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT03530085,https://clinicaltrials.gov/study/NCT06351306,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT03256071
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05184842,https://clinicaltrials.gov/study/NCT06379360,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT04905810,https://clinicaltrials.gov/study/NCT04763928,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT06351306,https://clinicaltrials.gov/study/NCT03256071,https://clinicaltrials.gov/study/NCT05799079,https://clinicaltrials.gov/study/NCT03530085,https://clinicaltrials.gov/study/NCT02781883,https://clinicaltrials.gov/study/NCT04752527,https://clinicaltrials.gov/study/NCT04746235,https://clinicaltrials.gov/study/NCT06429098
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03836209
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Terminated	https://clinicaltrials.gov/study/NCT03063203,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT01177540,https://clinicaltrials.gov/study/NCT04051996
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT03080766,https://clinicaltrials.gov/study/NCT01809392,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT03356080
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03836209
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT00943553
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03836209
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03836209
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Completed	https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT03280030
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Completed	https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT03280030
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT01477606
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Completed	https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01830361
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01883362
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Completed	https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01830361
EFO_0000222	acute myeloid leukemia	CHEMBL1201182	TEMSIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT01611116
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Completed	https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT03280030
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Completed	https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01830361
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Completed	https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT03280030
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Terminated	https://clinicaltrials.gov/study/NCT01106950,https://clinicaltrials.gov/study/NCT01289678,https://clinicaltrials.gov/study/NCT01464359
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01106950,https://clinicaltrials.gov/study/NCT01289678,https://clinicaltrials.gov/study/NCT01464359
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT01639456
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Withdrawn	https://clinicaltrials.gov/study/NCT02723435,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT02723435,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05904106
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Terminated	https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT00798213
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Withdrawn	https://clinicaltrials.gov/study/NCT02723435,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL1201550	DENILEUKIN DIFTITOX	Protein	Interleukin-2 receptor binding agent		IL2RB	interleukin 2 receptor subunit beta	2	Terminated	https://clinicaltrials.gov/study/NCT01106950
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT02593123,https://clinicaltrials.gov/study/NCT01542944,https://clinicaltrials.gov/study/NCT02282215,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00469014
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT02782546
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT02427919,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00151242
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00488592,https://clinicaltrials.gov/study/NCT02593123,https://clinicaltrials.gov/study/NCT01700673
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha 	2	Completed	https://clinicaltrials.gov/study/NCT01700673,https://clinicaltrials.gov/study/NCT02593123,https://clinicaltrials.gov/study/NCT00488592
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL657	DIPHENHYDRAMINE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	2	Recruiting	https://clinicaltrials.gov/study/NCT05285813
EFO_0000222	acute myeloid leukemia	CHEMBL1201821	PALIFERMIN	Protein	Fibroblast growth factor receptor 2 agonist		FGFR2	fibroblast growth factor receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00629798
EFO_0000222	acute myeloid leukemia	CHEMBL1229517	VEMURAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Completed	https://clinicaltrials.gov/study/NCT03338348
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Recruiting	https://clinicaltrials.gov/study/NCT02416388
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT02416388
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT02610777
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT03709576
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03745352
EFO_0000222	acute myeloid leukemia	CHEMBL1286	LEVETIRACETAM	Small molecule	Voltage-gated N-type calcium channel alpha-1B subunit blocker		CACNA1B	calcium voltage-gated channel subunit alpha1 B	2	Terminated	https://clinicaltrials.gov/study/NCT01464359
EFO_0000222	acute myeloid leukemia	CHEMBL1289926	AXITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00071006
EFO_0000222	acute myeloid leukemia	CHEMBL1289926	AXITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00071006
EFO_0000222	acute myeloid leukemia	CHEMBL1289926	AXITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00071006
EFO_0000222	acute myeloid leukemia	CHEMBL1289926	AXITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT00893373,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT03170895
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT00893373,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT03170895,https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT03170895,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00893373
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT03170895,https://clinicaltrials.gov/study/NCT00893373,https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT00893373,https://clinicaltrials.gov/study/NCT03170895
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT06447090,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1425	MERCAPTOPURINE ANHYDROUS	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	2	Terminated	https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02782546
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT02782546
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	2	Terminated	https://clinicaltrials.gov/study/NCT04002115
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	2	Terminated	https://clinicaltrials.gov/study/NCT04002115
EFO_0000222	acute myeloid leukemia	CHEMBL1467	ALLOPURINOL	Small molecule	Xanthine dehydrogenase inhibitor		XDH	xanthine dehydrogenase	2	Terminated	https://clinicaltrials.gov/study/NCT01464359
EFO_0000222	acute myeloid leukemia	CHEMBL1471	APREPITANT	Small molecule	Neurokinin 1 receptor antagonist		TACR1	tachykinin receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01334086
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04023526,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04266795,https://clinicaltrials.gov/study/NCT03466294,https://clinicaltrials.gov/study/NCT04150029
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT01413880
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05736965,https://clinicaltrials.gov/study/NCT04062266,https://clinicaltrials.gov/study/NCT05413018,https://clinicaltrials.gov/study/NCT05401097,https://clinicaltrials.gov/study/NCT05736978,https://clinicaltrials.gov/study/NCT03383575,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT05197426,https://clinicaltrials.gov/study/NCT06022003,https://clinicaltrials.gov/study/NCT05305859,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT06105658,https://clinicaltrials.gov/study/NCT04867928,https://clinicaltrials.gov/study/NCT06379360,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT05442216,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT03573024,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT05404906,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT04905810,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT06014489,https://clinicaltrials.gov/study/NCT04913922,https://clinicaltrials.gov/study/NCT04905407,https://clinicaltrials.gov/study/NCT03769532,https://clinicaltrials.gov/study/NCT05175508,https://clinicaltrials.gov/study/NCT04248595,https://clinicaltrials.gov/study/NCT06220162,https://clinicaltrials.gov/study/NCT06317649
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT01413880
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT01556477,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT00728520
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01556477,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT00728520
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT02204020,https://clinicaltrials.gov/study/NCT06180863,https://clinicaltrials.gov/study/NCT03745352
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT01413880
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT04968015
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT02756962
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT01015196,https://clinicaltrials.gov/study/NCT01806571
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT04687098
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05554393
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT00952588
EFO_0000222	acute myeloid leukemia	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01843179
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	2	Completed	https://clinicaltrials.gov/study/NCT00136448,https://clinicaltrials.gov/study/NCT00005940,https://clinicaltrials.gov/study/NCT01252667
EFO_0000222	acute myeloid leukemia	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	2	Recruiting	https://clinicaltrials.gov/study/NCT02416388
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00850304
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00744081
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00744081
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT00744081
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00143975
EFO_0000222	acute myeloid leukemia	CHEMBL1643	RIBAVIRIN	Small molecule	Inosine-5'-monophosphate dehydrogenase 1 inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	2	Completed	https://clinicaltrials.gov/study/NCT00559091,https://clinicaltrials.gov/study/NCT02073838
EFO_0000222	acute myeloid leukemia	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor		CD38	CD38 molecule	2	Completed	https://clinicaltrials.gov/study/NCT02807558
EFO_0000222	acute myeloid leukemia	CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor		CD38	CD38 molecule	2	Terminated	https://clinicaltrials.gov/study/NCT03067571
EFO_0000222	acute myeloid leukemia	CHEMBL1743018	FICLATUZUMAB	Antibody	Hepatocyte growth factor inhibitor		HGF	hepatocyte growth factor	2	Withdrawn	https://clinicaltrials.gov/study/NCT04100330
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT01806571
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT06451861
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT05554393
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT06451861
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT05554393
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT04415008
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05805098
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT04415008
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT03181815
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT05241093
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT04425655
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT04425655
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00863434
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT01066494
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT02502968
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT03381781
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT03381781
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT02275663
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT01039363
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT04100330
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT02587871
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT00967512
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03324243
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT04100330
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT04100330
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT00044889
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT01457885
EFO_0000222	acute myeloid leukemia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRA	retinoid X receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00615784
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT02686593
EFO_0000222	acute myeloid leukemia	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02341495
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT01025154
EFO_0000222	acute myeloid leukemia	CHEMBL109	VALPROIC ACID	Small molecule	Succinate semialdehyde dehydrogenase inhibitor		ALDH5A1	aldehyde dehydrogenase 5 family member A1	2	Completed	https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00414310,https://clinicaltrials.gov/study/NCT00326170,https://clinicaltrials.gov/study/NCT00339196
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00469014
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT01295307
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05917405,https://clinicaltrials.gov/study/NCT04989335
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335,https://clinicaltrials.gov/study/NCT05917405
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335,https://clinicaltrials.gov/study/NCT05917405
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05917405,https://clinicaltrials.gov/study/NCT04989335
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Recruiting	https://clinicaltrials.gov/study/NCT05917405,https://clinicaltrials.gov/study/NCT04989335
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335,https://clinicaltrials.gov/study/NCT05917405
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02250937
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT03128359
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT03128359
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT00070135
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT03128359
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT01960387
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01960387
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT00939653
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT03128359
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00939653
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT00070135
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT00863434
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT04002115
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Recruiting	https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	2	Completed	https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00546897,https://clinicaltrials.gov/study/NCT02472691,https://clinicaltrials.gov/study/NCT01301820,https://clinicaltrials.gov/study/NCT00761449,https://clinicaltrials.gov/study/NCT01358734,https://clinicaltrials.gov/study/NCT01743859,https://clinicaltrials.gov/study/NCT00360672,https://clinicaltrials.gov/study/NCT00957385
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	2	Completed	https://clinicaltrials.gov/study/NCT01301820,https://clinicaltrials.gov/study/NCT02472691,https://clinicaltrials.gov/study/NCT00546897,https://clinicaltrials.gov/study/NCT01358734,https://clinicaltrials.gov/study/NCT00761449,https://clinicaltrials.gov/study/NCT00360672,https://clinicaltrials.gov/study/NCT01743859,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00957385
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00863434
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT04002115
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	2	Terminated	https://clinicaltrials.gov/study/NCT01442714,https://clinicaltrials.gov/study/NCT00720850
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01556477
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	2	Unknown status	https://clinicaltrials.gov/study/NCT01556477
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT00863434
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	2	Unknown status	https://clinicaltrials.gov/study/NCT01556477
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01556477
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT04069208
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT00209833
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05285813
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Vanilloid receptor opener		TRPV1	transient receptor potential cation channel subfamily V member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05285813
EFO_0000222	acute myeloid leukemia	CHEMBL1171837	PONATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		BCR	BCR activator of RhoGEF and GTPase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04188405,https://clinicaltrials.gov/study/NCT03690115
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT01253070
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT02337478,https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00130702
EFO_0000222	acute myeloid leukemia	CHEMBL1200751	MERCAPTOPURINE	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	2	Terminated	https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00707408
EFO_0000222	acute myeloid leukemia	CHEMBL1200976	IDARUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01015196
EFO_0000222	acute myeloid leukemia	CHEMBL1200976	IDARUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00707408
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT01413880
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT05939180,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05361057
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00209833
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04353479
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01177540,https://clinicaltrials.gov/study/NCT04051996,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT03063203
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT01809392,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT03080766
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT01550224,https://clinicaltrials.gov/study/NCT01617226,https://clinicaltrials.gov/study/NCT00656617
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00943553
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	2	Terminated	https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01039363
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT01039363
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT01370213,https://clinicaltrials.gov/study/NCT00136448,https://clinicaltrials.gov/study/NCT02763475
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT01370213,https://clinicaltrials.gov/study/NCT00136448,https://clinicaltrials.gov/study/NCT02763475
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT01639456,https://clinicaltrials.gov/study/NCT04354025
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03374332,https://clinicaltrials.gov/study/NCT03839446
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Completed	https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00882102,https://clinicaltrials.gov/study/NCT04173585,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT02221310,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT01698879,https://clinicaltrials.gov/study/NCT00037583,https://clinicaltrials.gov/study/NCT00909168,https://clinicaltrials.gov/study/NCT02117297,https://clinicaltrials.gov/study/NCT00968071,https://clinicaltrials.gov/study/NCT02473146,https://clinicaltrials.gov/study/NCT00044733
EFO_0000222	acute myeloid leukemia	CHEMBL1873475	IBRUTINIB	Small molecule	Tyrosine-protein kinase BTK inhibitor		BTK	Bruton tyrosine kinase	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03642236
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT03737955,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT05199051
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT01039363
EFO_0000222	acute myeloid leukemia	CHEMBL1201550	DENILEUKIN DIFTITOX	Protein	Interleukin-2 receptor binding agent		IL2RA	interleukin 2 receptor subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01106950
EFO_0000222	acute myeloid leukemia	CHEMBL1201550	DENILEUKIN DIFTITOX	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	2	Terminated	https://clinicaltrials.gov/study/NCT01106950
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04824924,https://clinicaltrials.gov/study/NCT04254640
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT04002115
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT04354025
EFO_0000222	acute myeloid leukemia	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT03045627
EFO_0000222	acute myeloid leukemia	CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent		MS4A1	membrane spanning 4-domains A1	2	Completed	https://clinicaltrials.gov/study/NCT03096782
EFO_0000222	acute myeloid leukemia	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha 	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04266795
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04266795
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	2	Completed	https://clinicaltrials.gov/study/NCT02610777
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	2	Terminated	https://clinicaltrials.gov/study/NCT03709576
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT03745352
EFO_0000222	acute myeloid leukemia	CHEMBL1233528	VOLASERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00804856
EFO_0000222	acute myeloid leukemia	CHEMBL1233528	VOLASERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02198482
EFO_0000224	acute promyelocytic leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Completed	https://clinicaltrials.gov/study/NCT00413166
EFO_0000224	acute promyelocytic leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT04793919,https://clinicaltrials.gov/study/NCT01409161
EFO_0000222	acute myeloid leukemia	CHEMBL1286	LEVETIRACETAM	Small molecule	Synaptic vesicle glycoprotein 2A modulator		SV2A	synaptic vesicle glycoprotein 2A	2	Terminated	https://clinicaltrials.gov/study/NCT01464359
EFO_0000222	acute myeloid leukemia	CHEMBL1289926	AXITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1289926	AXITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL2035187	PACRITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02532010
EFO_0000222	acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	2	Completed	https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT01841333
EFO_0000222	acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	2	Terminated	https://clinicaltrials.gov/study/NCT04051996
EFO_0000222	acute myeloid leukemia	CHEMBL2095208	COBICISTAT	Small molecule	Cytochrome P450 3A inhibitor		CYP3A43	cytochrome P450 family 3 subfamily A member 43	2	Recruiting	https://clinicaltrials.gov/study/NCT06014489
EFO_0000222	acute myeloid leukemia	CHEMBL2095208	COBICISTAT	Small molecule	Cytochrome P450 3A inhibitor		CYP3A5	cytochrome P450 family 3 subfamily A member 5	2	Recruiting	https://clinicaltrials.gov/study/NCT06014489
EFO_0000222	acute myeloid leukemia	CHEMBL2095208	COBICISTAT	Small molecule	Cytochrome P450 3A inhibitor		CYP3A7	cytochrome P450 family 3 subfamily A member 7	2	Recruiting	https://clinicaltrials.gov/study/NCT06014489
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		METAP2	methionyl aminopeptidase 2	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT03170895,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT00893373,https://clinicaltrials.gov/study/NCT02474290
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		DNPEP	aspartyl aminopeptidase	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		NPEPPS	aminopeptidase puromycin sensitive	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT03170895,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT00893373
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		RNPEPL1	arginyl aminopeptidase like 1	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00893373,https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT03170895,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT00373373
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ERAP2	endoplasmic reticulum aminopeptidase 2	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ANPEP	alanyl aminopeptidase, membrane	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00373373,https://clinicaltrials.gov/study/NCT02474290,https://clinicaltrials.gov/study/NCT03622541,https://clinicaltrials.gov/study/NCT03170895,https://clinicaltrials.gov/study/NCT00893373
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		LAP3	leucine aminopeptidase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		XPNPEP1	X-prolyl aminopeptidase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		DNPEP	aspartyl aminopeptidase	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		NPEPPS	aminopeptidase puromycin sensitive	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		RNPEPL1	arginyl aminopeptidase like 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		METAP1	methionyl aminopeptidase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ERAP1	endoplasmic reticulum aminopeptidase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		METAP1D	methionyl aminopeptidase type 1D, mitochondrial	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		RNPEP	arginyl aminopeptidase	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		NPEPL1	aminopeptidase like 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT04326439
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01907815
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT03324243
EFO_0000222	acute myeloid leukemia	CHEMBL2107832	PIMASERTIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00957580
EFO_0000222	acute myeloid leukemia	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02275533,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Terminated	https://clinicaltrials.gov/study/NCT03381118
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL1 inhibitor		KIR2DL1	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1	2	Completed	https://clinicaltrials.gov/study/NCT01687387
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000275546	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Completed	https://clinicaltrials.gov/study/NCT01687387
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000276011	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Completed	https://clinicaltrials.gov/study/NCT01687387
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000276731	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Completed	https://clinicaltrials.gov/study/NCT01687387
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000278731	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Completed	https://clinicaltrials.gov/study/NCT01687387
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL3 inhibitor		KIR2DL3	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3	2	Terminated	https://clinicaltrials.gov/study/NCT02399917
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000275546	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Terminated	https://clinicaltrials.gov/study/NCT02399917
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000276731	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Terminated	https://clinicaltrials.gov/study/NCT02399917
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000278731	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Terminated	https://clinicaltrials.gov/study/NCT02399917
EFO_0000222	acute myeloid leukemia	CHEMBL2109630	BC8 131I	Antibody	Leukocyte common antigen binding agent		PTPRC	protein tyrosine phosphatase receptor type C	2	Completed	https://clinicaltrials.gov/study/NCT00005940
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02113319
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL2263632	ASLAN-003	Small molecule	Dihydroorotate dehydrogenase inhibitor		DHODH	dihydroorotate dehydrogenase (quinone)	2	Completed	https://clinicaltrials.gov/study/NCT03451084
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA8	EPH receptor A8	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA6	EPH receptor A6	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB6	EPH receptor B6	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB2	EPH receptor B2	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA7	EPH receptor A7	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA5	EPH receptor A5	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06055621
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA1	EPH receptor A1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA10	EPH receptor A10	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL25202	TAMIBAROTENE	Small molecule	Retinoic acid receptor beta agonist		RARB	retinoic acid receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT02807558
EFO_0000222	acute myeloid leukemia	CHEMBL25202	TAMIBAROTENE	Small molecule	Retinoic acid receptor alpha agonist		RARA	retinoic acid receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT02807558
EFO_0000222	acute myeloid leukemia	CHEMBL25202	TAMIBAROTENE	Small molecule	Retinoic acid receptor alpha agonist		RARA	retinoic acid receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04905407
EFO_0000222	acute myeloid leukemia	CHEMBL25336	BISANTRENE	Small molecule	Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor		FTO	FTO alpha-ketoglutarate dependent dioxygenase	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT01690065
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 8 inhibitor		HDAC8	histone deacetylase 8	2	Terminated	https://clinicaltrials.gov/study/NCT00666497,https://clinicaltrials.gov/study/NCT00374296
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 11 inhibitor		HDAC11	histone deacetylase 11	2	Terminated	https://clinicaltrials.gov/study/NCT00666497,https://clinicaltrials.gov/study/NCT00374296
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00374296,https://clinicaltrials.gov/study/NCT00666497
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00354146,https://clinicaltrials.gov/study/NCT00048503
EFO_0000222	acute myeloid leukemia	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT00048503,https://clinicaltrials.gov/study/NCT00354146
EFO_0000222	acute myeloid leukemia	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	2	Unknown status	https://clinicaltrials.gov/study/NCT00510939
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	2	Completed	https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT02593123,https://clinicaltrials.gov/study/NCT03096782
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	2	Completed	https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT02593123,https://clinicaltrials.gov/study/NCT03128359,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Recruiting	https://clinicaltrials.gov/study/NCT05583175,https://clinicaltrials.gov/study/NCT05404906,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT05939180,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT04867928,https://clinicaltrials.gov/study/NCT05736965,https://clinicaltrials.gov/study/NCT04062266,https://clinicaltrials.gov/study/NCT04746235,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT05807347,https://clinicaltrials.gov/study/NCT06014489,https://clinicaltrials.gov/study/NCT04905810,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT05184842,https://clinicaltrials.gov/study/NCT05401097,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT04763928,https://clinicaltrials.gov/study/NCT06317649,https://clinicaltrials.gov/study/NCT06105658,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT05305859,https://clinicaltrials.gov/study/NCT04752527,https://clinicaltrials.gov/study/NCT05736978,https://clinicaltrials.gov/study/NCT06220162,https://clinicaltrials.gov/study/NCT05833438,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT06191263,https://clinicaltrials.gov/study/NCT04905407,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT03573024,https://clinicaltrials.gov/study/NCT05431257,https://clinicaltrials.gov/study/NCT05799079,https://clinicaltrials.gov/study/NCT05603884
EFO_0000222	acute myeloid leukemia	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01907815
EFO_0000222	acute myeloid leukemia	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01907815
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04023526,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03466294,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04150029,https://clinicaltrials.gov/study/NCT04266795
EFO_0000222	acute myeloid leukemia	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02768792
EFO_0000222	acute myeloid leukemia	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT02771197,https://clinicaltrials.gov/study/NCT02845297,https://clinicaltrials.gov/study/NCT02708641
EFO_0000222	acute myeloid leukemia	CHEMBL3237547	CEDAZURIDINE	Small molecule	Cytidine deaminase inhibitor		CDA	cytidine deaminase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04975919
EFO_0000222	acute myeloid leukemia	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	2	Completed	https://clinicaltrials.gov/study/NCT04173585,https://clinicaltrials.gov/study/NCT01736943,https://clinicaltrials.gov/study/NCT01420926
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Completed	https://clinicaltrials.gov/study/NCT02017457,https://clinicaltrials.gov/study/NCT03338348,https://clinicaltrials.gov/study/NCT01743859,https://clinicaltrials.gov/study/NCT01462578,https://clinicaltrials.gov/study/NCT01700673,https://clinicaltrials.gov/study/NCT02610777,https://clinicaltrials.gov/study/NCT01301820,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT00795548,https://clinicaltrials.gov/study/NCT02450877,https://clinicaltrials.gov/study/NCT00326170,https://clinicaltrials.gov/study/NCT01617226,https://clinicaltrials.gov/study/NCT00339196,https://clinicaltrials.gov/study/NCT01488565,https://clinicaltrials.gov/study/NCT01912274,https://clinicaltrials.gov/study/NCT05048615,https://clinicaltrials.gov/study/NCT00915785,https://clinicaltrials.gov/study/NCT02807558,https://clinicaltrials.gov/study/NCT02775903,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT01541280,https://clinicaltrials.gov/study/NCT01358734,https://clinicaltrials.gov/study/NCT02472691,https://clinicaltrials.gov/study/NCT00382590
EFO_0000222	acute myeloid leukemia	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	2	Unknown status	https://clinicaltrials.gov/study/NCT00510939
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Completed	https://clinicaltrials.gov/study/NCT02450877,https://clinicaltrials.gov/study/NCT01488565,https://clinicaltrials.gov/study/NCT00795548,https://clinicaltrials.gov/study/NCT01743859,https://clinicaltrials.gov/study/NCT01462578,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT05048615,https://clinicaltrials.gov/study/NCT02775903,https://clinicaltrials.gov/study/NCT01700673,https://clinicaltrials.gov/study/NCT00326170,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT01912274,https://clinicaltrials.gov/study/NCT00915785,https://clinicaltrials.gov/study/NCT02472691,https://clinicaltrials.gov/study/NCT01541280,https://clinicaltrials.gov/study/NCT02610777,https://clinicaltrials.gov/study/NCT02807558,https://clinicaltrials.gov/study/NCT03338348,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00339196,https://clinicaltrials.gov/study/NCT01301820,https://clinicaltrials.gov/study/NCT01617226,https://clinicaltrials.gov/study/NCT01358734,https://clinicaltrials.gov/study/NCT02017457
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT06384261,https://clinicaltrials.gov/study/NCT06456463,https://clinicaltrials.gov/study/NCT06232655,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT05904106
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT06022003
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06456463,https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT06232655,https://clinicaltrials.gov/study/NCT06384261,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT05904106,https://clinicaltrials.gov/study/NCT05628623
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05736978,https://clinicaltrials.gov/study/NCT06220162,https://clinicaltrials.gov/study/NCT04905407,https://clinicaltrials.gov/study/NCT04867928,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT05413018,https://clinicaltrials.gov/study/NCT04248595,https://clinicaltrials.gov/study/NCT06014489,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT06105658,https://clinicaltrials.gov/study/NCT05404906,https://clinicaltrials.gov/study/NCT03573024,https://clinicaltrials.gov/study/NCT03769532,https://clinicaltrials.gov/study/NCT05736965,https://clinicaltrials.gov/study/NCT06022003,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT05197426,https://clinicaltrials.gov/study/NCT04062266,https://clinicaltrials.gov/study/NCT04905810,https://clinicaltrials.gov/study/NCT04913922,https://clinicaltrials.gov/study/NCT03383575,https://clinicaltrials.gov/study/NCT05401097,https://clinicaltrials.gov/study/NCT06317649,https://clinicaltrials.gov/study/NCT05442216,https://clinicaltrials.gov/study/NCT06379360,https://clinicaltrials.gov/study/NCT05175508,https://clinicaltrials.gov/study/NCT05305859
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Terminated	https://clinicaltrials.gov/study/NCT03709576,https://clinicaltrials.gov/study/NCT02399917,https://clinicaltrials.gov/study/NCT01442714,https://clinicaltrials.gov/study/NCT00666497,https://clinicaltrials.gov/study/NCT00446303,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT02351037,https://clinicaltrials.gov/study/NCT02341495,https://clinicaltrials.gov/study/NCT02942758
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02341495,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT01442714,https://clinicaltrials.gov/study/NCT00666497,https://clinicaltrials.gov/study/NCT02399917,https://clinicaltrials.gov/study/NCT03709576,https://clinicaltrials.gov/study/NCT02351037,https://clinicaltrials.gov/study/NCT00446303,https://clinicaltrials.gov/study/NCT02942758
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT06022003,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT06317649,https://clinicaltrials.gov/study/NCT05199051
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT06180863,https://clinicaltrials.gov/study/NCT02204020,https://clinicaltrials.gov/study/NCT03745352
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT06317649,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT06022003,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Recruiting	https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT03121014
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Terminated	https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT01773395
EFO_0000222	acute myeloid leukemia	CHEMBL1542	AZATHIOPRINE	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04824924
EFO_0000222	acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05736965,https://clinicaltrials.gov/study/NCT05951855,https://clinicaltrials.gov/study/NCT05736978
EFO_0000222	acute myeloid leukemia	CHEMBL1542	AZATHIOPRINE	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	2	Recruiting	https://clinicaltrials.gov/study/NCT05833438
EFO_0000222	acute myeloid leukemia	CHEMBL3545395	BI-811283	Small molecule	Serine/threonine-protein kinase Aurora-B inhibitor		AURKB	aurora kinase B	2	Completed	https://clinicaltrials.gov/study/NCT00632749
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT01843179
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04015024
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL159	VINBLASTINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00136461,https://clinicaltrials.gov/study/NCT00326170,https://clinicaltrials.gov/study/NCT00867672
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00326170,https://clinicaltrials.gov/study/NCT00867672,https://clinicaltrials.gov/study/NCT00136461
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT05175508
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05175508
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT05175508
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02942758
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT03356080
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	2	Unknown status	https://clinicaltrials.gov/study/NCT03356080
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00744081
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03609060
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05285813
EFO_0000222	acute myeloid leukemia	CHEMBL389621	HYDROCORTISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Terminated	https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT03071276
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03383575,https://clinicaltrials.gov/study/NCT04203316,https://clinicaltrials.gov/study/NCT05401097
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT03881735
EFO_0000222	acute myeloid leukemia	CHEMBL3989931	ENASIDENIB MESYLATE	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04203316
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3D	CD3 delta subunit of T-cell receptor complex	2	Recruiting	https://clinicaltrials.gov/study/NCT04582864
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04582864
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	2	Recruiting	https://clinicaltrials.gov/study/NCT04582864
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3E	CD3 epsilon subunit of T-cell receptor complex	2	Withdrawn	https://clinicaltrials.gov/study/NCT05063123
EFO_0000222	acute myeloid leukemia	CHEMBL408194	OBATOCLAX	Small molecule	Bcl-2-like protein 10 inhibitor		BCL2L10	BCL2 like 10	2	Completed	https://clinicaltrials.gov/study/NCT00684918
EFO_0000222	acute myeloid leukemia	CHEMBL408194	OBATOCLAX	Small molecule	Apoptosis regulator Bcl-X inhibitor		BCL2L1	BCL2 like 1	2	Completed	https://clinicaltrials.gov/study/NCT00684918
EFO_0000222	acute myeloid leukemia	CHEMBL408194	OBATOCLAX	Small molecule	Apoptosis regulator Bcl-W inhibitor		BCL2L2-PABPN1	BCL2L2-PABPN1 readthrough	2	Completed	https://clinicaltrials.gov/study/NCT00684918
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL4204794	AVAPRITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT03969420
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT03969420,https://clinicaltrials.gov/study/NCT02520011
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	2	Terminated	https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT03969420
EFO_0000222	acute myeloid leukemia	CHEMBL4297235	OMBIPEPIMUT-S	Unknown	Wilms tumor protein vaccine antigen		WT1	WT1 transcription factor	2	Recruiting	https://clinicaltrials.gov/study/NCT04747002
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06456463
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	2	Recruiting	https://clinicaltrials.gov/study/NCT04342962,https://clinicaltrials.gov/study/NCT05442216
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT03096782
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT00067028
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01295307
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT02686593
EFO_0000222	acute myeloid leukemia	CHEMBL4297763	GTI-2040	Unknown	Ribonucleotide reductase small subunit mRNA antisense inhibitor		RRM2	ribonucleotide reductase regulatory subunit M2	2	Completed	https://clinicaltrials.gov/study/NCT00565058
EFO_0000222	acute myeloid leukemia	CHEMBL4297837	TALACOTUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	2	Terminated	https://clinicaltrials.gov/study/NCT02992860
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00469014,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT01025154
EFO_0000222	acute myeloid leukemia	CHEMBL4297871	CAMIDANLUMAB TESIRINE	Antibody drug conjugate	Interleukin-2 receptor alpha chain binding agent		IL2RA	interleukin 2 receptor subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT04639024
EFO_0000222	acute myeloid leukemia	CHEMBL4297891	CUSATUZUMAB	Antibody	CD70 antigen inhibitor		CD70	CD70 molecule	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06384261
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT01188174,https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT01457885,https://clinicaltrials.gov/study/NCT01252667,https://clinicaltrials.gov/study/NCT01295307,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00373529,https://clinicaltrials.gov/study/NCT00924443,https://clinicaltrials.gov/study/NCT00044889,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00042354,https://clinicaltrials.gov/study/NCT00469014
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335,https://clinicaltrials.gov/study/NCT05917405
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335,https://clinicaltrials.gov/study/NCT05917405
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335,https://clinicaltrials.gov/study/NCT05917405
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05917405,https://clinicaltrials.gov/study/NCT04989335
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05917405,https://clinicaltrials.gov/study/NCT04989335
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04989335,https://clinicaltrials.gov/study/NCT05917405
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT02349178
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT02349178
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT00863434
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Completed	https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT01180322
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01025778,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT01180322
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT05955261
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT02848183
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT02848183
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Binding agent	CD33	CD33 molecule	2	Completed	https://clinicaltrials.gov/study/NCT00528333
EFO_0000222	acute myeloid leukemia	CHEMBL4594575	SABATOLIMAB	Antibody	Hepatitis A virus cellular receptor 2 inhibitor		HAVCR2	hepatitis A virus cellular receptor 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04150029
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL3 inhibitor		KIR2DL3	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3	2	Completed	https://clinicaltrials.gov/study/NCT01687387
EFO_0000222	acute myeloid leukemia	CHEMBL461101	ELTROMBOPAG	Small molecule	Thrombopoietin receptor agonist		MPL	MPL proto-oncogene, thrombopoietin receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02446145
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000275914	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Completed	https://clinicaltrials.gov/study/NCT01687387
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL1 inhibitor		KIR2DL1	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1	2	Terminated	https://clinicaltrials.gov/study/NCT02399917
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000275914	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Terminated	https://clinicaltrials.gov/study/NCT02399917
EFO_0000222	acute myeloid leukemia	CHEMBL2109500	LIRILUMAB	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000276011	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	2	Terminated	https://clinicaltrials.gov/study/NCT02399917
EFO_0000222	acute myeloid leukemia	CHEMBL2219774	GATAPARSEN	Oligonucleotide	Survivin mRNA antisense inhibitor		BIRC5	baculoviral IAP repeat containing 5	2	Completed	https://clinicaltrials.gov/study/NCT00620321
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA3	EPH receptor A3	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase BRK inhibitor		PTK6	protein tyrosine kinase 6	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA4	EPH receptor A4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA2	EPH receptor A2	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB1	EPH receptor B1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB3	EPH receptor B3	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB4	EPH receptor B4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL25202	TAMIBAROTENE	Small molecule	Retinoic acid receptor beta agonist		RARB	retinoic acid receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT04905407
EFO_0000222	acute myeloid leukemia	CHEMBL25336	BISANTRENE	Small molecule	Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor		FTO	FTO alpha-ketoglutarate dependent dioxygenase	2	Completed	https://clinicaltrials.gov/study/NCT03820908
EFO_0000222	acute myeloid leukemia	CHEMBL467	HYDROXYUREA	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM2	ribonucleotide reductase regulatory subunit M2	2	Completed	https://clinicaltrials.gov/study/NCT02088541
EFO_0000222	acute myeloid leukemia	CHEMBL467	HYDROXYUREA	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM2	ribonucleotide reductase regulatory subunit M2	2	Recruiting	https://clinicaltrials.gov/study/NCT05062278
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01806571
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT01806571
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Unknown status	https://clinicaltrials.gov/study/NCT01690065
EFO_0000222	acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT03096782,https://clinicaltrials.gov/study/NCT00070135,https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT03128359
EFO_0000222	acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Recruiting	https://clinicaltrials.gov/study/NCT03121014,https://clinicaltrials.gov/study/NCT02782546
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Terminated	https://clinicaltrials.gov/study/NCT04002115,https://clinicaltrials.gov/study/NCT01773395
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00374296,https://clinicaltrials.gov/study/NCT00666497
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00666497,https://clinicaltrials.gov/study/NCT00374296
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01305499
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT00466115
EFO_0000222	acute myeloid leukemia	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT00510939
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT03466294,https://clinicaltrials.gov/study/NCT03455504,https://clinicaltrials.gov/study/NCT04975919,https://clinicaltrials.gov/study/NCT04266795,https://clinicaltrials.gov/study/NCT02250937,https://clinicaltrials.gov/study/NCT04150029,https://clinicaltrials.gov/study/NCT04188405,https://clinicaltrials.gov/study/NCT04267081
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Completed	https://clinicaltrials.gov/study/NCT04476199,https://clinicaltrials.gov/study/NCT01994837,https://clinicaltrials.gov/study/NCT05048615
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06284486,https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT05904106,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT06232655,https://clinicaltrials.gov/study/NCT06456463,https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT04824924,https://clinicaltrials.gov/study/NCT06384261,https://clinicaltrials.gov/study/NCT05356169
EFO_0000222	acute myeloid leukemia	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01907815
EFO_0000222	acute myeloid leukemia	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03769532
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL3237547	CEDAZURIDINE	Small molecule	Cytidine deaminase inhibitor		CDA	cytidine deaminase	2	Recruiting	https://clinicaltrials.gov/study/NCT05799079,https://clinicaltrials.gov/study/NCT04746235,https://clinicaltrials.gov/study/NCT06351306
EFO_0000222	acute myeloid leukemia	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	2	Terminated	https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT02775903
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT06022003
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT02927262
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT02927262
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT01529827,https://clinicaltrials.gov/study/NCT00005940,https://clinicaltrials.gov/study/NCT00070135
EFO_0000222	acute myeloid leukemia	CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor		CD38	CD38 molecule	2	Terminated	https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	2	Completed	https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT02249091
EFO_0000222	acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	2	Terminated	https://clinicaltrials.gov/study/NCT03071276
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00129948
EFO_0000222	acute myeloid leukemia	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01736943
EFO_0000222	acute myeloid leukemia	CHEMBL3674570	EDICOTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT03557970
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04015024
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04015024
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	2	Completed	https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00136461,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00867672,https://clinicaltrials.gov/study/NCT00326170
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT02942758
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	2	Terminated	https://clinicaltrials.gov/study/NCT02942758
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT03356080
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Unknown status	https://clinicaltrials.gov/study/NCT01423175
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Terminated	https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03825796
EFO_0000222	acute myeloid leukemia	CHEMBL3989931	ENASIDENIB MESYLATE	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03825796
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT04562792,https://clinicaltrials.gov/study/NCT01015196,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT01999413
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT05554393
EFO_0000222	acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05401097
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL3989971	UPROLESELAN	Small molecule	Selectin E antagonist		SELE	selectin E	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL3989978	PREXIGEBERSEN	Oligonucleotide	Growth factor receptor-bound protein 2 mRNA antisense inhibitor		GRB2	growth factor receptor bound protein 2	2	Recruiting	https://clinicaltrials.gov/study/NCT02781883
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03286530
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03286530
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL1873475	IBRUTINIB	Small molecule	Tyrosine-protein kinase BTK inhibitor		BTK	Bruton tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT02351037
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3G	CD3 gamma subunit of T-cell receptor complex	2	Recruiting	https://clinicaltrials.gov/study/NCT04582864
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3E	CD3 epsilon subunit of T-cell receptor complex	2	Recruiting	https://clinicaltrials.gov/study/NCT04582864
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3G	CD3 gamma subunit of T-cell receptor complex	2	Withdrawn	https://clinicaltrials.gov/study/NCT05063123
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3D	CD3 delta subunit of T-cell receptor complex	2	Withdrawn	https://clinicaltrials.gov/study/NCT05063123
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT05063123
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	2	Withdrawn	https://clinicaltrials.gov/study/NCT05063123
EFO_0000222	acute myeloid leukemia	CHEMBL3990044	RELATLIMAB	Antibody	Lymphocyte activation gene 3 protein inhibitor		LAG3	lymphocyte activating 3	2	Recruiting	https://clinicaltrials.gov/study/NCT04913922
EFO_0000222	acute myeloid leukemia	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL408194	OBATOCLAX	Small molecule	Apoptosis regulator Bcl-W inhibitor		BCL2L2	BCL2 like 2	2	Completed	https://clinicaltrials.gov/study/NCT00684918
EFO_0000222	acute myeloid leukemia	CHEMBL408194	OBATOCLAX	Small molecule	Bcl-2-related protein A1 inhibitor		BCL2A1	BCL2 related protein A1	2	Completed	https://clinicaltrials.gov/study/NCT00684918
EFO_0000222	acute myeloid leukemia	CHEMBL408194	OBATOCLAX	Small molecule	Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor		MCL1	MCL1 apoptosis regulator, BCL2 family member	2	Completed	https://clinicaltrials.gov/study/NCT00684918
EFO_0000222	acute myeloid leukemia	CHEMBL408194	OBATOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Completed	https://clinicaltrials.gov/study/NCT00684918
EFO_0000222	acute myeloid leukemia	CHEMBL2035187	PACRITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT02532010
EFO_0000222	acute myeloid leukemia	CHEMBL2095208	COBICISTAT	Small molecule	Cytochrome P450 3A inhibitor		CYP3A4	cytochrome P450 family 3 subfamily A member 4	2	Recruiting	https://clinicaltrials.gov/study/NCT06014489
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00798213
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	2	Terminated	https://clinicaltrials.gov/study/NCT00798213
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 5 inhibitor		CDK5	cyclin dependent kinase 5	2	Terminated	https://clinicaltrials.gov/study/NCT00798213
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00798213
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		LAP3	leucine aminopeptidase 3	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		XPNPEP1	X-prolyl aminopeptidase 1	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		LNPEP	leucyl and cystinyl aminopeptidase	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		XPNPEP2	X-prolyl aminopeptidase 2	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ENPEP	glutamyl aminopeptidase	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		AOPEP	aminopeptidase O (putative)	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		METAP1	methionyl aminopeptidase 1	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ERAP1	endoplasmic reticulum aminopeptidase 1	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		METAP1D	methionyl aminopeptidase type 1D, mitochondrial	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		LVRN	laeverin	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT00357032
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		RNPEP	arginyl aminopeptidase	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL413	SIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT00235560
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		XPNPEP3	X-prolyl aminopeptidase 3	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		NPEPL1	aminopeptidase like 1	2	Completed	https://clinicaltrials.gov/study/NCT00780598
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		METAP2	methionyl aminopeptidase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		LNPEP	leucyl and cystinyl aminopeptidase	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		XPNPEP2	X-prolyl aminopeptidase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ENPEP	glutamyl aminopeptidase	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		AOPEP	aminopeptidase O (putative)	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ERAP2	endoplasmic reticulum aminopeptidase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		ANPEP	alanyl aminopeptidase, membrane	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		LVRN	laeverin	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL415049	BARASERTIB	Small molecule	Serine/threonine-protein kinase Aurora-B inhibitor		AURKB	aurora kinase B	2	Completed	https://clinicaltrials.gov/study/NCT00952588
EFO_0000222	acute myeloid leukemia	CHEMBL2103847	TOSEDOSTAT	Small molecule	Aminopeptidase inhibitor		XPNPEP3	X-prolyl aminopeptidase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT01180426
EFO_0000222	acute myeloid leukemia	CHEMBL4204794	AVAPRITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT06221683
EFO_0000222	acute myeloid leukemia	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01907815
EFO_0000222	acute myeloid leukemia	CHEMBL2105107	INECALCITOL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02802267
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT01522469,https://clinicaltrials.gov/study/NCT02400255,https://clinicaltrials.gov/study/NCT01657682
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT01522469,https://clinicaltrials.gov/study/NCT02400255,https://clinicaltrials.gov/study/NCT01657682
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT01657682,https://clinicaltrials.gov/study/NCT02400255,https://clinicaltrials.gov/study/NCT01522469,https://clinicaltrials.gov/study/NCT02283177
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT03324243
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT03324243
EFO_0000222	acute myeloid leukemia	CHEMBL2107832	PIMASERTIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00957580
EFO_0000222	acute myeloid leukemia	CHEMBL2108280	CENERSEN	Oligonucleotide	p53 mRNA antisense inhibitor		TP53	tumor protein p53	2	Completed	https://clinicaltrials.gov/study/NCT00074737
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT03969420,https://clinicaltrials.gov/study/NCT02520011
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	2	Terminated	https://clinicaltrials.gov/study/NCT03969420,https://clinicaltrials.gov/study/NCT02520011
EFO_0000222	acute myeloid leukemia	CHEMBL2108280	CENERSEN	Oligonucleotide	p53 mRNA antisense inhibitor		TP53	tumor protein p53	2	Withdrawn	https://clinicaltrials.gov/study/NCT00967512
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT03969420
EFO_0000222	acute myeloid leukemia	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04913922
EFO_0000222	acute myeloid leukemia	CHEMBL2109128	LENOGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT01180322
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06456463
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06456463
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04342962,https://clinicaltrials.gov/study/NCT05442216
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05442216,https://clinicaltrials.gov/study/NCT04342962
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT03435848
EFO_0000222	acute myeloid leukemia	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04353479
EFO_0000222	acute myeloid leukemia	CHEMBL4297837	TALACOTUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT02472145
EFO_0000222	acute myeloid leukemia	CHEMBL4297837	TALACOTUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	2	Completed	https://clinicaltrials.gov/study/NCT02472145
EFO_0000222	acute myeloid leukemia	CHEMBL4297837	TALACOTUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02992860
EFO_0000222	acute myeloid leukemia	CHEMBL4297891	CUSATUZUMAB	Antibody	CD70 antigen inhibitor		CD70	CD70 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04023526
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT03839446
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03839446,https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Recruiting	https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Terminated	https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT02349178,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT00939653
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT01677949
EFO_0000222	acute myeloid leukemia	CHEMBL461101	ELTROMBOPAG	Small molecule	Thrombopoietin receptor agonist		MPL	MPL proto-oncogene, thrombopoietin receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03603795
EFO_0000222	acute myeloid leukemia	CHEMBL461101	ELTROMBOPAG	Small molecule	Thrombopoietin receptor agonist		MPL	MPL proto-oncogene, thrombopoietin receptor	2	Completed	https://clinicaltrials.gov/study/NCT01488565
EFO_0000222	acute myeloid leukemia	CHEMBL4650827	REVUMENIB	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		KMT2A	lysine methyltransferase 2A	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06284486
EFO_0000222	acute myeloid leukemia	CHEMBL4650827	REVUMENIB	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		MEN1	menin 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06284486
EFO_0000222	acute myeloid leukemia	CHEMBL467	HYDROXYUREA	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM2	ribonucleotide reductase regulatory subunit M2	2	Terminated	https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL473417	VISMODEGIB	Small molecule	Smoothened homolog inhibitor		SMO	smoothened, frizzled class receptor	2	Completed	https://clinicaltrials.gov/study/NCT02073838
EFO_0000222	acute myeloid leukemia	CHEMBL473417	VISMODEGIB	Small molecule	Smoothened homolog inhibitor		SMO	smoothened, frizzled class receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01880437
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01361334
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	2	Completed	https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT00830518
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT00880269
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT02665143
EFO_0000222	acute myeloid leukemia	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03953898
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL5314391	XL-999	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00322673
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04107727
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04107727
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04107727
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00989261,https://clinicaltrials.gov/study/NCT02984995,https://clinicaltrials.gov/study/NCT01565668
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT04209725
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT04209725
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT03135054
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT03135054
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03839446,https://clinicaltrials.gov/study/NCT03164057
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT02686593,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00774046
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT06447090,https://clinicaltrials.gov/study/NCT06262438
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02848183
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Terminated	https://clinicaltrials.gov/study/NCT02438761
EFO_0000222	acute myeloid leukemia	CHEMBL595	PIOGLITAZONE	Small molecule	Peroxisome proliferator-activated receptor gamma agonist		PPARG	peroxisome proliferator activated receptor gamma	2	Terminated	https://clinicaltrials.gov/study/NCT02942758
EFO_0000222	acute myeloid leukemia	CHEMBL601719	CRIZOTINIB	Small molecule	NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)		ALK	ALK receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT00003875
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Completed	https://clinicaltrials.gov/study/NCT00003875
EFO_0000330	childhood acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003875
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT03836209
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Completed	https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01883362
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Completed	https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT01477606
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01830361,https://clinicaltrials.gov/study/NCT03280030
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Completed	https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT01830361
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Completed	https://clinicaltrials.gov/study/NCT01883362,https://clinicaltrials.gov/study/NCT03280030,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01830361
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Recruiting	https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Terminated	https://clinicaltrials.gov/study/NCT03951961
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT02723435,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT02723435,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Withdrawn	https://clinicaltrials.gov/study/NCT02723435,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Withdrawn	https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT02723435
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT03338348
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT02392429
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT03092674,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT01413880
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03836209,https://clinicaltrials.gov/study/NCT04107727,https://clinicaltrials.gov/study/NCT03164057,https://clinicaltrials.gov/study/NCT02756962,https://clinicaltrials.gov/study/NCT04914676,https://clinicaltrials.gov/study/NCT02392429,https://clinicaltrials.gov/study/NCT01413880,https://clinicaltrials.gov/study/NCT04968015,https://clinicaltrials.gov/study/NCT03825796,https://clinicaltrials.gov/study/NCT03092674
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT01477606
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT00382590
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT00334074
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT00774046
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT01723657,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00074737
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT00620321,https://clinicaltrials.gov/study/NCT01546038,https://clinicaltrials.gov/study/NCT00037596,https://clinicaltrials.gov/study/NCT01838395,https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00915252,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT01253070,https://clinicaltrials.gov/study/NCT01999413,https://clinicaltrials.gov/study/NCT00804856,https://clinicaltrials.gov/study/NCT00151242,https://clinicaltrials.gov/study/NCT00632749,https://clinicaltrials.gov/study/NCT00195000,https://clinicaltrials.gov/study/NCT00382590,https://clinicaltrials.gov/study/NCT00067028,https://clinicaltrials.gov/study/NCT01019317,https://clinicaltrials.gov/study/NCT00850304,https://clinicaltrials.gov/study/NCT02283177,https://clinicaltrials.gov/study/NCT00273884,https://clinicaltrials.gov/study/NCT00774046,https://clinicaltrials.gov/study/NCT00334074,https://clinicaltrials.gov/study/NCT01716793,https://clinicaltrials.gov/study/NCT00952588,https://clinicaltrials.gov/study/NCT02088541,https://clinicaltrials.gov/study/NCT01477606,https://clinicaltrials.gov/study/NCT01829503,https://clinicaltrials.gov/study/NCT00143975,https://clinicaltrials.gov/study/NCT00422591,https://clinicaltrials.gov/study/NCT02873338,https://clinicaltrials.gov/study/NCT00074737,https://clinicaltrials.gov/study/NCT01247493,https://clinicaltrials.gov/study/NCT00822094,https://clinicaltrials.gov/study/NCT01025154,https://clinicaltrials.gov/study/NCT01180322,https://clinicaltrials.gov/study/NCT04687098,https://clinicaltrials.gov/study/NCT00528333,https://clinicaltrials.gov/study/NCT02560025,https://clinicaltrials.gov/study/NCT02249091,https://clinicaltrials.gov/study/NCT03335267,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT00778375,https://clinicaltrials.gov/study/NCT01806571,https://clinicaltrials.gov/study/NCT00079482,https://clinicaltrials.gov/study/NCT00788892,https://clinicaltrials.gov/study/NCT01723657
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT05554393
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT05628623
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT04254640
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT05554393
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT06451861
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT04254640,https://clinicaltrials.gov/study/NCT05554393
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05554393,https://clinicaltrials.gov/study/NCT05628623,https://clinicaltrials.gov/study/NCT06451861,https://clinicaltrials.gov/study/NCT04254640
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT05906914
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT02416388
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT02115295
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT04195945,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT04050280
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03793517,https://clinicaltrials.gov/study/NCT05361057,https://clinicaltrials.gov/study/NCT03586609,https://clinicaltrials.gov/study/NCT03629171,https://clinicaltrials.gov/study/NCT06068621,https://clinicaltrials.gov/study/NCT06084819,https://clinicaltrials.gov/study/NCT05199051,https://clinicaltrials.gov/study/NCT04415008,https://clinicaltrials.gov/study/NCT03181815,https://clinicaltrials.gov/study/NCT04050280,https://clinicaltrials.gov/study/NCT03591510,https://clinicaltrials.gov/study/NCT02416388,https://clinicaltrials.gov/study/NCT05260528,https://clinicaltrials.gov/study/NCT06221683,https://clinicaltrials.gov/study/NCT03150004,https://clinicaltrials.gov/study/NCT05805098,https://clinicaltrials.gov/study/NCT06429098,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT05955261,https://clinicaltrials.gov/study/NCT05599360,https://clinicaltrials.gov/study/NCT05906914,https://clinicaltrials.gov/study/NCT04069208,https://clinicaltrials.gov/study/NCT05603884,https://clinicaltrials.gov/study/NCT06262438,https://clinicaltrials.gov/study/NCT05241093,https://clinicaltrials.gov/study/NCT00801489,https://clinicaltrials.gov/study/NCT06434662,https://clinicaltrials.gov/study/NCT04801797,https://clinicaltrials.gov/study/NCT04195945
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Suspended	https://clinicaltrials.gov/study/NCT03701308
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT02229266
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT01960387
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT01794169
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT01193400
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT02520011,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT01588951
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT03381118,https://clinicaltrials.gov/study/NCT00863434,https://clinicaltrials.gov/study/NCT04425655,https://clinicaltrials.gov/study/NCT00593645,https://clinicaltrials.gov/study/NCT01034410,https://clinicaltrials.gov/study/NCT02419755,https://clinicaltrials.gov/study/NCT00939653,https://clinicaltrials.gov/study/NCT01588951,https://clinicaltrials.gov/study/NCT01794169,https://clinicaltrials.gov/study/NCT02229266,https://clinicaltrials.gov/study/NCT01193400,https://clinicaltrials.gov/study/NCT04326439,https://clinicaltrials.gov/study/NCT04209725,https://clinicaltrials.gov/study/NCT02198482,https://clinicaltrials.gov/study/NCT01880437,https://clinicaltrials.gov/study/NCT04526288,https://clinicaltrials.gov/study/NCT01960387,https://clinicaltrials.gov/study/NCT02433483,https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT03071276,https://clinicaltrials.gov/study/NCT02532010,https://clinicaltrials.gov/study/NCT02520011
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT00559221
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT03381781
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT02272478,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT00209833
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02937662,https://clinicaltrials.gov/study/NCT00529880,https://clinicaltrials.gov/study/NCT01039363,https://clinicaltrials.gov/study/NCT02848183,https://clinicaltrials.gov/study/NCT03045627,https://clinicaltrials.gov/study/NCT02502968,https://clinicaltrials.gov/study/NCT02275663,https://clinicaltrials.gov/study/NCT00209833,https://clinicaltrials.gov/study/NCT03356080,https://clinicaltrials.gov/study/NCT01066494,https://clinicaltrials.gov/study/NCT00559221,https://clinicaltrials.gov/study/NCT03381781,https://clinicaltrials.gov/study/NCT02638428,https://clinicaltrials.gov/study/NCT02272478
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT00967512,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03207334
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT04100330,https://clinicaltrials.gov/study/NCT01843179,https://clinicaltrials.gov/study/NCT03324243,https://clinicaltrials.gov/study/NCT02587871,https://clinicaltrials.gov/study/NCT03207334,https://clinicaltrials.gov/study/NCT04354025,https://clinicaltrials.gov/study/NCT00967512
EFO_0000222	acute myeloid leukemia	CHEMBL84	TOPOTECAN	Small molecule	DNA topoisomerase I, mitochondrial inhibitor		TOP1MT	DNA topoisomerase I mitochondrial	2	Completed	https://clinicaltrials.gov/study/NCT00744081
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	2	Completed	https://clinicaltrials.gov/study/NCT01301820,https://clinicaltrials.gov/study/NCT02472691,https://clinicaltrials.gov/study/NCT00360672,https://clinicaltrials.gov/study/NCT00957385,https://clinicaltrials.gov/study/NCT00546897,https://clinicaltrials.gov/study/NCT01743859,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT01358734,https://clinicaltrials.gov/study/NCT00761449
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	2	Completed	https://clinicaltrials.gov/study/NCT02472691,https://clinicaltrials.gov/study/NCT00360672,https://clinicaltrials.gov/study/NCT00546897,https://clinicaltrials.gov/study/NCT01301820,https://clinicaltrials.gov/study/NCT01743859,https://clinicaltrials.gov/study/NCT00957385,https://clinicaltrials.gov/study/NCT01358734,https://clinicaltrials.gov/study/NCT03118466,https://clinicaltrials.gov/study/NCT00761449
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	2	Terminated	https://clinicaltrials.gov/study/NCT00720850,https://clinicaltrials.gov/study/NCT01442714
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	2	Terminated	https://clinicaltrials.gov/study/NCT00720850,https://clinicaltrials.gov/study/NCT01442714
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	2	Terminated	https://clinicaltrials.gov/study/NCT00720850,https://clinicaltrials.gov/study/NCT01442714
EFO_0000222	acute myeloid leukemia	CHEMBL866	MYCOPHENOLIC ACID	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02416388
EFO_0000222	acute myeloid leukemia	CHEMBL866	MYCOPHENOLIC ACID	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT02416388
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT02337478,https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT02337478,https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT03860844,https://clinicaltrials.gov/study/NCT02337478
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT02337478,https://clinicaltrials.gov/study/NCT03860844
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT02337478,https://clinicaltrials.gov/study/NCT03860844
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003875
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00707408,https://clinicaltrials.gov/study/NCT00744081
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT00744081,https://clinicaltrials.gov/study/NCT00707408
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02638428
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00594555
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT01550224,https://clinicaltrials.gov/study/NCT01617226,https://clinicaltrials.gov/study/NCT00656617
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT01617226,https://clinicaltrials.gov/study/NCT01550224
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT01550224,https://clinicaltrials.gov/study/NCT00656617,https://clinicaltrials.gov/study/NCT01617226
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02419755
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Terminated	https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02419755
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	2	Unknown status	https://clinicaltrials.gov/study/NCT01039363
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT01039363
EFO_0000330	childhood acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT01529827
EFO_0000224	acute promyelocytic leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	2	Withdrawn	https://clinicaltrials.gov/study/NCT01548911
EFO_1001934	adult acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1001934	adult acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1001934	adult acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02835222
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL4204794	AVAPRITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05821738
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL4204794	AVAPRITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05821738
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Recruiting	https://clinicaltrials.gov/study/NCT03686345
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
EFO_1002001	core binding factor acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05404516
MONDO_0015667	acute myeloid leukemia by FAB classification	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT02520102
MONDO_0015667	acute myeloid leukemia by FAB classification	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha 	2	Withdrawn	https://clinicaltrials.gov/study/NCT02520102
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200976	IDARUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Completed	https://clinicaltrials.gov/study/NCT00492401
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Completed	https://clinicaltrials.gov/study/NCT00492401
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05449899
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02634827,https://clinicaltrials.gov/study/NCT01846624
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418,https://clinicaltrials.gov/study/NCT04284787
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418,https://clinicaltrials.gov/study/NCT04284787
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05513131
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04284787,https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04284787
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL413	SIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Completed	https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT02634827,https://clinicaltrials.gov/study/NCT01846624
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	2	Terminated	https://clinicaltrials.gov/study/NCT02634827,https://clinicaltrials.gov/study/NCT01846624
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02583893,https://clinicaltrials.gov/study/NCT02286726
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT02583893,https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249,https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249,https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	2	Completed	https://clinicaltrials.gov/study/NCT02126553
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	2	Completed	https://clinicaltrials.gov/study/NCT02126553
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	2	Completed	https://clinicaltrials.gov/study/NCT02126553
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249,https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05449899
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05449899
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	2	Completed	https://clinicaltrials.gov/study/NCT01529827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05513131
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00531232
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02286726
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Recruiting	https://clinicaltrials.gov/study/NCT05513131,https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT05780879
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	2	Terminated	https://clinicaltrials.gov/study/NCT02634827,https://clinicaltrials.gov/study/NCT01846624
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT02634827,https://clinicaltrials.gov/study/NCT01846624
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02634827,https://clinicaltrials.gov/study/NCT01846624
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	2	Terminated	https://clinicaltrials.gov/study/NCT01846624,https://clinicaltrials.gov/study/NCT02634827
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	2	Terminated	https://clinicaltrials.gov/study/NCT02634827,https://clinicaltrials.gov/study/NCT01846624
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03226418
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT02583893
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT02583893,https://clinicaltrials.gov/study/NCT01238211,https://clinicaltrials.gov/study/NCT02286726
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT02286726,https://clinicaltrials.gov/study/NCT02583893,https://clinicaltrials.gov/study/NCT01238211
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249,https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249,https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04214249,https://clinicaltrials.gov/study/NCT02115295
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT02115295,https://clinicaltrials.gov/study/NCT04214249
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00209833
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	2	Completed	https://clinicaltrials.gov/study/NCT02126553
EFO_0000222	acute myeloid leukemia	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL101253	VATALANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL101253	VATALANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRG	retinoid X receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT00316030,https://clinicaltrials.gov/study/NCT01001143
EFO_0000222	acute myeloid leukemia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRB	retinoid X receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT01001143,https://clinicaltrials.gov/study/NCT00316030
EFO_0000222	acute myeloid leukemia	CHEMBL109	VALPROIC ACID	Small molecule	Succinate semialdehyde dehydrogenase inhibitor		ALDH5A1	aldehyde dehydrogenase 5 family member A1	1	Completed	https://clinicaltrials.gov/study/NCT01575691,https://clinicaltrials.gov/study/NCT00175812,https://clinicaltrials.gov/study/NCT00995332
EFO_0000222	acute myeloid leukemia	CHEMBL109	VALPROIC ACID	Small molecule	Succinate semialdehyde dehydrogenase inhibitor		ALDH5A1	aldehyde dehydrogenase 5 family member A1	1	Unknown status	https://clinicaltrials.gov/study/NCT01369368
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT01787474
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL5095030	MOTIXAFORTIDE	Protein	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	1	Terminated	https://clinicaltrials.gov/study/NCT03154827
EFO_0000222	acute myeloid leukemia	CHEMBL5095034	SOVLEPLENIB	Small molecule	Tyrosine-protein kinase SYK inhibitor		SYK	spleen associated tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT03483948
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02649764
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT01787474
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT01787474
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT02649764
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT02057770
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT01701323
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT01701323
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Terminated	https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT02057770
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT02057770
EFO_0000222	acute myeloid leukemia	CHEMBL5314406	4SC-203	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT01054937
EFO_0000222	acute myeloid leukemia	CHEMBL5314406	4SC-203	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01054937
EFO_0000222	acute myeloid leukemia	CHEMBL5314406	4SC-203	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01054937
EFO_0000222	acute myeloid leukemia	CHEMBL5314406	4SC-203	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01054937
EFO_0000222	acute myeloid leukemia	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00783653,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00783653
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00783653
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00783653
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00783653
EFO_0000222	acute myeloid leukemia	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT01020539
EFO_0000222	acute myeloid leukemia	CHEMBL571209	INDOXIMOD	Small molecule	mTORC1 activator		RPTOR	regulatory associated protein of MTOR complex 1	1	Completed	https://clinicaltrials.gov/study/NCT02835729
EFO_0000222	acute myeloid leukemia	CHEMBL571209	INDOXIMOD	Small molecule	mTORC1 activator		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT02835729
EFO_0000222	acute myeloid leukemia	CHEMBL571546	TIRBANIBULIN	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01397799
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04112589
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04112589
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04112589
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01236144,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT00462761,https://clinicaltrials.gov/study/NCT03723681,https://clinicaltrials.gov/study/NCT01468467,https://clinicaltrials.gov/study/NCT03735875,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT02675478,https://clinicaltrials.gov/study/NCT01411267
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT02675478,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT01236144,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT00462761,https://clinicaltrials.gov/study/NCT01468467,https://clinicaltrials.gov/study/NCT03735875,https://clinicaltrials.gov/study/NCT03723681
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Recruiting	https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04128748
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT03661307
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT03793478
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT03552029
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT00878722,https://clinicaltrials.gov/study/NCT00382954,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT03194932
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT03214562
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Completed	https://clinicaltrials.gov/study/NCT04580121
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	1	Completed	https://clinicaltrials.gov/study/NCT04580121
EFO_0000222	acute myeloid leukemia	CHEMBL1171837	PONATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02400281
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05522192
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT05345938,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT02631252,https://clinicaltrials.gov/study/NCT00660036
EFO_0000222	acute myeloid leukemia	CHEMBL1171837	PONATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		BCR	BCR activator of RhoGEF and GTPase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02829840
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT05330377
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01578109
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01578109
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL1200645	ETOPOSIDE PHOSPHATE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT01249430
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL1200645	ETOPOSIDE PHOSPHATE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Completed	https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT00045942
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT01161550
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Completed	https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT00977782
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Completed	https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT02078609
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT00977782
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Completed	https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT04075747
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Completed	https://clinicaltrials.gov/study/NCT01001143,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT01798901,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT00986804,https://clinicaltrials.gov/study/NCT02109744,https://clinicaltrials.gov/study/NCT01352650,https://clinicaltrials.gov/study/NCT01149408,https://clinicaltrials.gov/study/NCT02093403,https://clinicaltrials.gov/study/NCT02996474,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT01455506,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT02878785,https://clinicaltrials.gov/study/NCT03063944,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT00538876,https://clinicaltrials.gov/study/NCT00671697,https://clinicaltrials.gov/study/NCT02632721,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT00479232,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT00861874
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT02078609
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Completed	https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01161550
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Completed	https://clinicaltrials.gov/study/NCT02093403,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01352650,https://clinicaltrials.gov/study/NCT02109744,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT00861874,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT00986804,https://clinicaltrials.gov/study/NCT02632721,https://clinicaltrials.gov/study/NCT00538876,https://clinicaltrials.gov/study/NCT03063944,https://clinicaltrials.gov/study/NCT00671697,https://clinicaltrials.gov/study/NCT02878785,https://clinicaltrials.gov/study/NCT00479232,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT02996474,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT01149408,https://clinicaltrials.gov/study/NCT01798901,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT01001143,https://clinicaltrials.gov/study/NCT01455506,https://clinicaltrials.gov/study/NCT01690507
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Completed	https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT01161550
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06129734,https://clinicaltrials.gov/study/NCT06401603,https://clinicaltrials.gov/study/NCT06484062
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03021395,https://clinicaltrials.gov/study/NCT04485052
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Suspended	https://clinicaltrials.gov/study/NCT04485052,https://clinicaltrials.gov/study/NCT03021395
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Terminated	https://clinicaltrials.gov/study/NCT03113071,https://clinicaltrials.gov/study/NCT02003573,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT02203773,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02343939
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT01758367,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT01277484
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391,https://clinicaltrials.gov/study/NCT03752138,https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391,https://clinicaltrials.gov/study/NCT03752138,https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00866281,https://clinicaltrials.gov/study/NCT04496999
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT06152809
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT04327037
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Recruiting	https://clinicaltrials.gov/study/NCT04347616,https://clinicaltrials.gov/study/NCT06158828
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT06158828,https://clinicaltrials.gov/study/NCT04347616
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT02770820,https://clinicaltrials.gov/study/NCT01898793,https://clinicaltrials.gov/study/NCT02781467
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	1	Completed	https://clinicaltrials.gov/study/NCT00038831,https://clinicaltrials.gov/study/NCT00766116,https://clinicaltrials.gov/study/NCT01020539,https://clinicaltrials.gov/study/NCT03848754,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT02182596,https://clinicaltrials.gov/study/NCT03390296
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT00669890,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT00660036,https://clinicaltrials.gov/study/NCT03878927
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	1	Unknown status	https://clinicaltrials.gov/study/NCT00460447
EFO_0000222	acute myeloid leukemia	CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist		IFNAR1	interferon alpha and beta receptor subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02328755
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02626338
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT03467386,https://clinicaltrials.gov/study/NCT03214562
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT02886559
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG2	gamma-aminobutyric acid type A receptor subunit gamma2	1	Completed	https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL1201587	ALEMTUZUMAB	Antibody	CAMPATH-1 antigen inhibitor		CD52	CD52 molecule	1	Completed	https://clinicaltrials.gov/study/NCT00458250
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG1	gamma-aminobutyric acid type A receptor subunit gamma1	1	Completed	https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00004918
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA5	gamma-aminobutyric acid type A receptor subunit alpha5	1	Completed	https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA1	gamma-aminobutyric acid type A receptor subunit alpha1	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA2	gamma-aminobutyric acid type A receptor subunit alpha2	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG1	gamma-aminobutyric acid type A receptor subunit gamma1	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT00246662
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03013998
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	1	Terminated	https://clinicaltrials.gov/study/NCT04172844
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT04172844
EFO_0000222	acute myeloid leukemia	CHEMBL1233528	VOLASERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01662505
EFO_0000222	acute myeloid leukemia	CHEMBL1233528	VOLASERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02003573
EFO_0000222	acute myeloid leukemia	CHEMBL1237022	TOCILIZUMAB	Antibody	Interleukin-6 receptor alpha subunit inhibitor		IL6R	interleukin 6 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT02057770
EFO_0000222	acute myeloid leukemia	CHEMBL124660	TANDUTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT00064584,https://clinicaltrials.gov/study/NCT00274248
EFO_0000222	acute myeloid leukemia	CHEMBL124660	TANDUTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00064584,https://clinicaltrials.gov/study/NCT00274248
EFO_0000222	acute myeloid leukemia	CHEMBL124660	TANDUTINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Withdrawn	https://clinicaltrials.gov/study/NCT00297921
EFO_0000222	acute myeloid leukemia	CHEMBL124660	TANDUTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT00297921
EFO_0000222	acute myeloid leukemia	CHEMBL124660	TANDUTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT00297921
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT03330821
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03330821,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT02632708
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT03330821
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT03330821,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT02632708
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT02530476
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03330821,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04190550
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02530476,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT01534260
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT02070458
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT02530476,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02270788
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT02530476,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT00943943
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT04402723,https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT04402723,https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT00780104
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT04402723,https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT04402723
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT01463046
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT01246622
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT01681537
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT00875693
EFO_0000222	acute myeloid leukemia	CHEMBL1393	SPIRONOLACTONE	Small molecule	Mineralocorticoid receptor antagonist		NR3C2	nuclear receptor subfamily 3 group C member 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03867682
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT02573363
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT05345938
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02891278
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00850382
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	1	Completed	https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00850382
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06007911,https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT06007911,https://clinicaltrials.gov/study/NCT05100303
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06007911,https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06007911,https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT05100303
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT03560908,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02923986
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03560908,https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT04049539
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT05665075
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT05319587
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT03214562
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05665114
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03900949,https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03983824,https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Suspended	https://clinicaltrials.gov/study/NCT03900949,https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03900949,https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT02343939
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT00907517
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT01701323
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT02255162
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT03634228
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT03031249
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02488408
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT03031249
EFO_0000222	acute myeloid leukemia	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03560882
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04755244,https://clinicaltrials.gov/study/NCT03825367,https://clinicaltrials.gov/study/NCT04086264,https://clinicaltrials.gov/study/NCT02677922,https://clinicaltrials.gov/study/NCT04150887,https://clinicaltrials.gov/study/NCT03513484,https://clinicaltrials.gov/study/NCT03530683,https://clinicaltrials.gov/study/NCT04742101,https://clinicaltrials.gov/study/NCT04435691
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02576301
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Completed	https://clinicaltrials.gov/study/NCT05155709,https://clinicaltrials.gov/study/NCT01835587,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT02367456,https://clinicaltrials.gov/study/NCT02995655,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT04629443,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT04241549,https://clinicaltrials.gov/study/NCT01575691,https://clinicaltrials.gov/study/NCT02782468,https://clinicaltrials.gov/study/NCT02071927,https://clinicaltrials.gov/study/NCT00766116,https://clinicaltrials.gov/study/NCT03390296,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT03298516,https://clinicaltrials.gov/study/NCT01519011,https://clinicaltrials.gov/study/NCT02543879,https://clinicaltrials.gov/study/NCT03701295,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT01814826,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT01390311,https://clinicaltrials.gov/study/NCT02750995,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT01016600,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT00761722,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT04887857
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT03031249
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02886559
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05949762,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT04964505,https://clinicaltrials.gov/study/NCT05834244,https://clinicaltrials.gov/study/NCT04623216,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT05471700,https://clinicaltrials.gov/study/NCT04501120,https://clinicaltrials.gov/study/NCT05270200,https://clinicaltrials.gov/study/NCT06285890,https://clinicaltrials.gov/study/NCT06449482,https://clinicaltrials.gov/study/NCT04358393,https://clinicaltrials.gov/study/NCT05226455,https://clinicaltrials.gov/study/NCT05662956,https://clinicaltrials.gov/study/NCT04980885,https://clinicaltrials.gov/study/NCT03113643,https://clinicaltrials.gov/study/NCT06150040,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT05287568
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT02905994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT02905994
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Terminated	https://clinicaltrials.gov/study/NCT04172844,https://clinicaltrials.gov/study/NCT03217838,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT04336982,https://clinicaltrials.gov/study/NCT02953561,https://clinicaltrials.gov/study/NCT03465540,https://clinicaltrials.gov/study/NCT02203773,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT03483948,https://clinicaltrials.gov/study/NCT00923234
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02905994,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT03465540,https://clinicaltrials.gov/study/NCT00923234,https://clinicaltrials.gov/study/NCT04336982,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT02953561,https://clinicaltrials.gov/study/NCT02203773,https://clinicaltrials.gov/study/NCT04172844,https://clinicaltrials.gov/study/NCT03217838,https://clinicaltrials.gov/study/NCT03483948
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT02905994,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT01478074
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT01369368
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01369368
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02905994,https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT02472626
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT02303782,https://clinicaltrials.gov/study/NCT03932318,https://clinicaltrials.gov/study/NCT02829840,https://clinicaltrials.gov/study/NCT04128020,https://clinicaltrials.gov/study/NCT05720988
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT02905994,https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02829840,https://clinicaltrials.gov/study/NCT05720988,https://clinicaltrials.gov/study/NCT04128020,https://clinicaltrials.gov/study/NCT03932318,https://clinicaltrials.gov/study/NCT02303782
EFO_0000222	acute myeloid leukemia	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 7 antagonist		TLR7	toll like receptor 7	1	Terminated	https://clinicaltrials.gov/study/NCT02631252
EFO_0000222	acute myeloid leukemia	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 9 antagonist		TLR9	toll like receptor 9	1	Terminated	https://clinicaltrials.gov/study/NCT02631252
EFO_0000222	acute myeloid leukemia	CHEMBL1542	AZATHIOPRINE	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	1	Completed	https://clinicaltrials.gov/study/NCT03030612
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT00093600
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT03724084
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	1	Completed	https://clinicaltrials.gov/study/NCT00458250,https://clinicaltrials.gov/study/NCT00303667
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL1643	RIBAVIRIN	Small molecule	Inosine-5'-monophosphate dehydrogenase 1 inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	1	Terminated	https://clinicaltrials.gov/study/NCT03760666
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tumor necrosis factor receptor superfamily member 8 inhibitor		TNFRSF8	TNF receptor superfamily member 8	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL1743018	FICLATUZUMAB	Antibody	Hepatocyte growth factor inhibitor		HGF	hepatocyte growth factor	1	Terminated	https://clinicaltrials.gov/study/NCT02109627
EFO_0000222	acute myeloid leukemia	CHEMBL1743067	SAMALIZUMAB	Antibody	OX-2 membrane glycoprotein inhibitor		CD200	CD200 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT03013998
EFO_0000222	acute myeloid leukemia	CHEMBL1743070	SILTUXIMAB	Antibody	Interleukin-6 inhibitor		IL6	interleukin 6	1	Recruiting	https://clinicaltrials.gov/study/NCT05697510
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01090167,https://clinicaltrials.gov/study/NCT00529360
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01090167,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT00529360
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL101253	VATALANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL101253	VATALANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRA	retinoid X receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT01001143,https://clinicaltrials.gov/study/NCT00316030
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02960646
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02960646
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02799147
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT00303667
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02799147
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT02799147
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02799147,https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02649764
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01701323
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01640301,https://clinicaltrials.gov/study/NCT02057770
EFO_0000222	acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT02057770,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL809	SERTRALINE	Small molecule	Serotonin transporter inhibitor		SLC6A4	solute carrier family 6 member 4	1	Completed	https://clinicaltrials.gov/study/NCT02891278
EFO_0000222	acute myeloid leukemia	CHEMBL84	TOPOTECAN	Small molecule	DNA topoisomerase I, mitochondrial inhibitor		TOP1MT	DNA topoisomerase I mitochondrial	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	1	Completed	https://clinicaltrials.gov/study/NCT01578954,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT01016600,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT01433965,https://clinicaltrials.gov/study/NCT00831766
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	1	Completed	https://clinicaltrials.gov/study/NCT01016600,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT01578954,https://clinicaltrials.gov/study/NCT01433965,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT01681537
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	1	Terminated	https://clinicaltrials.gov/study/NCT00839059,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT00923234,https://clinicaltrials.gov/study/NCT02038153
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	1	Terminated	https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT02038153,https://clinicaltrials.gov/study/NCT00923234,https://clinicaltrials.gov/study/NCT00839059
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	1	Terminated	https://clinicaltrials.gov/study/NCT02038153,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT00839059,https://clinicaltrials.gov/study/NCT00923234
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT01518556,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT03330821
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT02440568
EFO_0000222	acute myeloid leukemia	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02905994
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Anandamide amidohydrolase inhibitor		FAAH	fatty acid amide hydrolase	1	Completed	https://clinicaltrials.gov/study/NCT04580121
EFO_0000222	acute myeloid leukemia	CHEMBL112	ACETAMINOPHEN	Small molecule	Vanilloid receptor opener		TRPV1	transient receptor potential cation channel subfamily V member 1	1	Completed	https://clinicaltrials.gov/study/NCT04580121
EFO_0000222	acute myeloid leukemia	CHEMBL1171837	PONATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1171837	PONATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02829840
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01578109
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01578109
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01578109
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1200751	MERCAPTOPURINE	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	1	Recruiting	https://clinicaltrials.gov/study/NCT05506332
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A2	ATPase Na+/K+ transporting subunit alpha 2	1	Terminated	https://clinicaltrials.gov/study/NCT03113071
EFO_0000222	acute myeloid leukemia	CHEMBL1200976	IDARUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04190550
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT02914977,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01773408
EFO_0000222	acute myeloid leukemia	CHEMBL1201081	METHYLPREDNISOLONE SODIUM SUCCINATE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02464657
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02204085,https://clinicaltrials.gov/study/NCT05222984,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT03009240,https://clinicaltrials.gov/study/NCT04657081,https://clinicaltrials.gov/study/NCT04277442
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05222984,https://clinicaltrials.gov/study/NCT02204085,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04657081,https://clinicaltrials.gov/study/NCT03009240,https://clinicaltrials.gov/study/NCT04277442
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06401603,https://clinicaltrials.gov/study/NCT06129734,https://clinicaltrials.gov/study/NCT06484062
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT00479232,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT00875745
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT04774393,https://clinicaltrials.gov/study/NCT03679650,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05010122,https://clinicaltrials.gov/study/NCT03132454,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT03844815,https://clinicaltrials.gov/study/NCT05396859,https://clinicaltrials.gov/study/NCT03041688,https://clinicaltrials.gov/study/NCT05190471,https://clinicaltrials.gov/study/NCT05010772
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT00479232
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT03904251
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03679650,https://clinicaltrials.gov/study/NCT03132454,https://clinicaltrials.gov/study/NCT05010122,https://clinicaltrials.gov/study/NCT03844815,https://clinicaltrials.gov/study/NCT03041688,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT04774393,https://clinicaltrials.gov/study/NCT05010772,https://clinicaltrials.gov/study/NCT05190471,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05396859
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05317403
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02203773,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT02003573,https://clinicaltrials.gov/study/NCT03113071
EFO_0000222	acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01277484,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT01758367,https://clinicaltrials.gov/study/NCT02886559
EFO_0000222	acute myeloid leukemia	CHEMBL1201265	METHYLPREDNISOLONE HEMISUCCINATE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02464657
EFO_0000222	acute myeloid leukemia	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03600155
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT06152809
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00303667,https://clinicaltrials.gov/study/NCT04327037
EFO_0000222	acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Terminated	https://clinicaltrials.gov/study/NCT02781467,https://clinicaltrials.gov/study/NCT01898793,https://clinicaltrials.gov/study/NCT02770820,https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL1201439	BASILIXIMAB	Antibody	Interleukin-2 receptor inhibitor		IL2RA	interleukin 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01842139
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04070768,https://clinicaltrials.gov/study/NCT04207190
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent	Binding agent	CD33	CD33 molecule	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05662904,https://clinicaltrials.gov/study/NCT06448013
EFO_0000222	acute myeloid leukemia	CHEMBL1795071	RUXOLITINIB PHOSPHATE	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL18442	PLERIXAFOR	Small molecule	C-X-C chemokine receptor type 4 partial agonist		CXCR4	C-X-C motif chemokine receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT00990054,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT01236144,https://clinicaltrials.gov/study/NCT01352650
EFO_0000222	acute myeloid leukemia	CHEMBL18442	PLERIXAFOR	Small molecule	C-X-C chemokine receptor type 4 partial agonist		CXCR4	C-X-C motif chemokine receptor 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT00396968
EFO_0000222	acute myeloid leukemia	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Recruiting	https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Unknown status	https://clinicaltrials.gov/study/NCT02310243
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Phosphodiesterase 4 inhibitor		PDE4C	phosphodiesterase 4C	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist		IFNAR2	interferon alpha and beta receptor subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02328755
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT01701323
EFO_0000222	acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT05330377
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Phosphodiesterase 3 inhibitor		PDE3B	phosphodiesterase 3B	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Adenosine receptor antagonist		ADORA1	adenosine A1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Adenosine receptor antagonist		ADORA2B	adenosine A2b receptor	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Phosphodiesterase 3 inhibitor		PDE3A	phosphodiesterase 3A	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT03214562
EFO_0000222	acute myeloid leukemia	CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent		MS4A1	membrane spanning 4-domains A1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03530683,https://clinicaltrials.gov/study/NCT04318678
EFO_0000222	acute myeloid leukemia	CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent		MS4A1	membrane spanning 4-domains A1	1	Completed	https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT00762632,https://clinicaltrials.gov/study/NCT01074086
EFO_0000222	acute myeloid leukemia	CHEMBL1908397	KW-2449	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00779480
EFO_0000222	acute myeloid leukemia	CHEMBL1908397	KW-2449	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT00779480
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha 	1	Completed	https://clinicaltrials.gov/study/NCT00004918
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03009240,https://clinicaltrials.gov/study/NCT03772925,https://clinicaltrials.gov/study/NCT03330821
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03009240,https://clinicaltrials.gov/study/NCT03772925,https://clinicaltrials.gov/study/NCT03330821
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	1	Completed	https://clinicaltrials.gov/study/NCT01814826,https://clinicaltrials.gov/study/NCT02782468
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02782468,https://clinicaltrials.gov/study/NCT01814826
EFO_0000222	acute myeloid leukemia	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	1	Recruiting	https://clinicaltrials.gov/study/NCT03013998
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	MAP kinase p38 beta inhibitor		MAPK11	mitogen-activated protein kinase 11	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Nerve growth factor receptor Trk-A		NTRK1	neurotrophic receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1233528	VOLASERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02722135,https://clinicaltrials.gov/study/NCT02905994
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1237022	TOCILIZUMAB	Antibody	Interleukin-6 receptor alpha subunit inhibitor		IL6R	interleukin 6 receptor	1	Completed	https://clinicaltrials.gov/study/NCT04547062,https://clinicaltrials.gov/study/NCT04580121
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL124660	TANDUTINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00064584,https://clinicaltrials.gov/study/NCT00274248
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	MAP kinase p38 beta inhibitor		MAPK11	mitogen-activated protein kinase 11	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Nerve growth factor receptor Trk-A		NTRK1	neurotrophic receptor tyrosine kinase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1983268	ENTRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK3	neurotrophic receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT05396859
EFO_0000222	acute myeloid leukemia	CHEMBL1983268	ENTRECTINIB	Small molecule	ALK tyrosine kinase receptor inhibitor		ALK	ALK receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT05396859
EFO_0000222	acute myeloid leukemia	CHEMBL1983268	ENTRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK1	neurotrophic receptor tyrosine kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05396859
EFO_0000222	acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT02530476
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT02530476
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT02530476,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT01398501
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02530476,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT01578109,https://clinicaltrials.gov/study/NCT00943943
EFO_0000222	acute myeloid leukemia	CHEMBL2095206	BOSUTINIB MONOHYDRATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT02530476,https://clinicaltrials.gov/study/NCT00943943,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT01398501,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01578109
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT03484520
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT04402723,https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT04402723,https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT04402723,https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT04402723
EFO_0000222	acute myeloid leukemia	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT04402723,https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Terminated	https://clinicaltrials.gov/study/NCT03484520
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 5 inhibitor		CDK5	cyclin dependent kinase 5	1	Terminated	https://clinicaltrials.gov/study/NCT03484520
EFO_0000222	acute myeloid leukemia	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02016729
EFO_0000222	acute myeloid leukemia	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01236144
EFO_0000222	acute myeloid leukemia	CHEMBL2105708	PONATINIB HYDROCHLORIDE	Small molecule	Bcr/Abl fusion protein inhibitor		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL2105717	CABOZANTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01961765
EFO_0000222	acute myeloid leukemia	CHEMBL2105717	CABOZANTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01961765
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT02270788
EFO_0000222	acute myeloid leukemia	CHEMBL1393	SPIRONOLACTONE	Small molecule	Mineralocorticoid receptor antagonist		NR3C2	nuclear receptor subfamily 3 group C member 2	1	Completed	https://clinicaltrials.gov/study/NCT02575963
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303
EFO_0000222	acute myeloid leukemia	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04277442,https://clinicaltrials.gov/study/NCT03600155,https://clinicaltrials.gov/study/NCT03825367
EFO_0000222	acute myeloid leukemia	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Completed	https://clinicaltrials.gov/study/NCT02464657
EFO_0000222	acute myeloid leukemia	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Terminated	https://clinicaltrials.gov/study/NCT02846376
EFO_0000222	acute myeloid leukemia	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04128020
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00850382
EFO_0000222	acute myeloid leukemia	CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Binding agent	CD33	CD33 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT00283114
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Binding agent	CD33	CD33 molecule	1	Withdrawn	https://clinicaltrials.gov/study/NCT03932318
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	1	Completed	https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00850382
EFO_0000222	acute myeloid leukemia	CHEMBL2109327	CSL-360	Antibody	Interleukin-3 receptor subunit alpha inhibitor		IL3RA	interleukin 3 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00401739
EFO_0000222	acute myeloid leukemia	CHEMBL2109498	IPH-2101	Antibody	Killer cell immunoglobulin-like receptor 2DL1 inhibitor		KIR2DL1	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1	1	Completed	https://clinicaltrials.gov/study/NCT01256073
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT04580121
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL2109498	IPH-2101	Antibody	Killer cell immunoglobulin-like receptor 2DL3 inhibitor		KIR2DL3	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3	1	Completed	https://clinicaltrials.gov/study/NCT01256073
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL2109498	IPH-2101	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000276731	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	1	Completed	https://clinicaltrials.gov/study/NCT01256073
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL2109498	IPH-2101	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000278731	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	1	Completed	https://clinicaltrials.gov/study/NCT01256073
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT03560908,https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03560908,https://clinicaltrials.gov/study/NCT02923986
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03560908,https://clinicaltrials.gov/study/NCT02923986
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT03560908,https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951
EFO_0000222	acute myeloid leukemia	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02923986,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03560908
EFO_0000222	acute myeloid leukemia	CHEMBL2141296	IXAZOMIB	Small molecule	26S proteasome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Completed	https://clinicaltrials.gov/study/NCT02070458
EFO_0000222	acute myeloid leukemia	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02670044
EFO_0000222	acute myeloid leukemia	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02670044
EFO_0000222	acute myeloid leukemia	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05441514
EFO_0000222	acute myeloid leukemia	CHEMBL2216870	IDELALISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT00710528,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL2316582	OLVEREMBATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06401603
EFO_0000222	acute myeloid leukemia	CHEMBL2316582	OLVEREMBATINIB	Small molecule	Bcr/Abl fusion protein inhibitor		BCR	BCR activator of RhoGEF and GTPase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06401603
EFO_0000222	acute myeloid leukemia	CHEMBL2386889	SCH-900776	Small molecule	Serine/threonine-protein kinase Chk1 inhibitor		CHEK1	checkpoint kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00907517
EFO_0000222	acute myeloid leukemia	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT02670044,https://clinicaltrials.gov/study/NCT01773408
EFO_0000222	acute myeloid leukemia	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Completed	https://clinicaltrials.gov/study/NCT02670044,https://clinicaltrials.gov/study/NCT01773408
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00762632
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT00762632
EFO_0000222	acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03247088
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 8 inhibitor		HDAC8	histone deacetylase 8	1	Completed	https://clinicaltrials.gov/study/NCT00324220
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT00324220
EFO_0000222	acute myeloid leukemia	CHEMBL274070	9-AMINOCAMPTOTHECIN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Completed	https://clinicaltrials.gov/study/NCT00251368
EFO_0000222	acute myeloid leukemia	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase HCK inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL288441	BOSUTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase Lyn inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL1425	MERCAPTOPURINE ANHYDROUS	Small molecule	Amidophosphoribosyltransferase inhibitor		PPAT	phosphoribosyl pyrophosphate amidotransferase	1	Recruiting	https://clinicaltrials.gov/study/NCT05506332
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00669890
EFO_0000222	acute myeloid leukemia	CHEMBL3039522	BIRINAPANT	Small molecule	cIAP1/cIAP2 inhibitor		BIRC3	baculoviral IAP repeat containing 3	1	Terminated	https://clinicaltrials.gov/study/NCT01486784
EFO_0000222	acute myeloid leukemia	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00669890
EFO_0000222	acute myeloid leukemia	CHEMBL3039522	BIRINAPANT	Small molecule	cIAP1/cIAP2 inhibitor		BIRC2	baculoviral IAP repeat containing 2	1	Terminated	https://clinicaltrials.gov/study/NCT01486784
EFO_0000222	acute myeloid leukemia	CHEMBL3040440	VS-4718	Small molecule	Focal adhesion kinase 1 inhibitor		PTK2	protein tyrosine kinase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02215629
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT04669067
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Recruiting	https://clinicaltrials.gov/study/NCT03041688
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Terminated	https://clinicaltrials.gov/study/NCT04113616
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06445907,https://clinicaltrials.gov/study/NCT06484062,https://clinicaltrials.gov/study/NCT06007911,https://clinicaltrials.gov/study/NCT06399640,https://clinicaltrials.gov/study/NCT06387420,https://clinicaltrials.gov/study/NCT06158100,https://clinicaltrials.gov/study/NCT06129734,https://clinicaltrials.gov/study/NCT06448013,https://clinicaltrials.gov/study/NCT06382168,https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Suspended	https://clinicaltrials.gov/study/NCT06191978
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Terminated	https://clinicaltrials.gov/study/NCT03484520,https://clinicaltrials.gov/study/NCT04092179,https://clinicaltrials.gov/study/NCT02203773,https://clinicaltrials.gov/study/NCT03217838,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT04336982,https://clinicaltrials.gov/study/NCT04172844
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03825367,https://clinicaltrials.gov/study/NCT03530683,https://clinicaltrials.gov/study/NCT04086264,https://clinicaltrials.gov/study/NCT03513484,https://clinicaltrials.gov/study/NCT04755244,https://clinicaltrials.gov/study/NCT02677922,https://clinicaltrials.gov/study/NCT04150887,https://clinicaltrials.gov/study/NCT04435691,https://clinicaltrials.gov/study/NCT04742101
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Completed	https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT04629443,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT05155709,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT01575691,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT01390311,https://clinicaltrials.gov/study/NCT00766116,https://clinicaltrials.gov/study/NCT02543879,https://clinicaltrials.gov/study/NCT03298516,https://clinicaltrials.gov/study/NCT02995655,https://clinicaltrials.gov/study/NCT00761722,https://clinicaltrials.gov/study/NCT02367456,https://clinicaltrials.gov/study/NCT01519011,https://clinicaltrials.gov/study/NCT01835587,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT03701295,https://clinicaltrials.gov/study/NCT02071927,https://clinicaltrials.gov/study/NCT04887857,https://clinicaltrials.gov/study/NCT04241549,https://clinicaltrials.gov/study/NCT02782468,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT03390296,https://clinicaltrials.gov/study/NCT02750995,https://clinicaltrials.gov/study/NCT01016600,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT01814826
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04207190
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT02878785
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT02878785
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06326697,https://clinicaltrials.gov/study/NCT06387420,https://clinicaltrials.gov/study/NCT06445907,https://clinicaltrials.gov/study/NCT06454409,https://clinicaltrials.gov/study/NCT06158100
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05319249
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05319249
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409,https://clinicaltrials.gov/study/NCT06387420,https://clinicaltrials.gov/study/NCT06445907,https://clinicaltrials.gov/study/NCT06158100,https://clinicaltrials.gov/study/NCT06326697
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05471700,https://clinicaltrials.gov/study/NCT05662956,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT04358393,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT05226455,https://clinicaltrials.gov/study/NCT05949762,https://clinicaltrials.gov/study/NCT04623216,https://clinicaltrials.gov/study/NCT04501120,https://clinicaltrials.gov/study/NCT04964505,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT04980885,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05287568,https://clinicaltrials.gov/study/NCT05270200,https://clinicaltrials.gov/study/NCT05834244,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT06150040,https://clinicaltrials.gov/study/NCT06285890,https://clinicaltrials.gov/study/NCT06449482,https://clinicaltrials.gov/study/NCT03113643
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Suspended	https://clinicaltrials.gov/study/NCT04485052
EFO_0000222	acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Suspended	https://clinicaltrials.gov/study/NCT04485052
EFO_0000222	acute myeloid leukemia	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Completed	https://clinicaltrials.gov/study/NCT02996474
EFO_0000222	acute myeloid leukemia	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Terminated	https://clinicaltrials.gov/study/NCT04372706,https://clinicaltrials.gov/study/NCT04478695
EFO_0000222	acute myeloid leukemia	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02312102
EFO_0000222	acute myeloid leukemia	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Completed	https://clinicaltrials.gov/study/NCT00651781,https://clinicaltrials.gov/study/NCT00382954,https://clinicaltrials.gov/study/NCT01534260
EFO_0000222	acute myeloid leukemia	CHEMBL3265032	ENTOSPLETINIB	Small molecule	Tyrosine-protein kinase SYK inhibitor		SYK	spleen associated tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT02343939
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL3301603	GILTERITINIB FUMARATE	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02310321
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02310321
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT06222580,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT05546580,https://clinicaltrials.gov/study/NCT05010122,https://clinicaltrials.gov/study/NCT05010772,https://clinicaltrials.gov/study/NCT03013998
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT05028751,https://clinicaltrials.gov/study/NCT04336982
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT05279859
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391,https://clinicaltrials.gov/study/NCT05279859,https://clinicaltrials.gov/study/NCT05330377
EFO_0000222	acute myeloid leukemia	CHEMBL3414621	TAZEMETOSTAT	Small molecule	Histone-lysine N-methyltransferase EZH2 inhibitor		EZH2	enhancer of zeste 2 polycomb repressive complex 2 subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05627232
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Completed	https://clinicaltrials.gov/study/NCT00458250,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02328755,https://clinicaltrials.gov/study/NCT03194932
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor	Inhibitor	DHFR	dihydrofolate reductase	1	Terminated	https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT00669890
EFO_0000222	acute myeloid leukemia	CHEMBL35	FUROSEMIDE	Small molecule	Sodium-(potassium)-chloride cotransporter 2 inhibitor		SLC12A1	solute carrier family 12 member 1	1	Completed	https://clinicaltrials.gov/study/NCT02575963
EFO_0000222	acute myeloid leukemia	CHEMBL3544911	PREXASERTIB	Small molecule	Serine/threonine-protein kinase Chk2 inhibitor		CHEK2	checkpoint kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02649764
EFO_0000222	acute myeloid leukemia	CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor		CD38	CD38 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03530683
EFO_0000222	acute myeloid leukemia	CHEMBL3545354	CAFUSERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02140606
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT02472626
EFO_0000222	acute myeloid leukemia	CHEMBL3545423	AZD-1208	Small molecule	Serine/threonine-protein kinase PIM inhibitor		PIM3	Pim-3 proto-oncogene, serine/threonine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01489722
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3545432	IXAZOMIB CITRATE	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Completed	https://clinicaltrials.gov/study/NCT02582359
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRDT	bromodomain testis associated	1	Withdrawn	https://clinicaltrials.gov/study/NCT02303782
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1567	SUNITINIB MALATE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3639788	TELAGLENASTAT	Small molecule	Glutaminase kidney isoform, mitochondrial inhibitor		GLS	glutaminase	1	Completed	https://clinicaltrials.gov/study/NCT02071927
EFO_0000222	acute myeloid leukemia	CHEMBL3653256	SIREMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT05155709
EFO_0000222	acute myeloid leukemia	CHEMBL3653256	SIREMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Completed	https://clinicaltrials.gov/study/NCT05155709
EFO_0000222	acute myeloid leukemia	CHEMBL3653256	SIREMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT05445154
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT05445154
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT02859948
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Unknown status	https://clinicaltrials.gov/study/NCT02859948
EFO_0000222	acute myeloid leukemia	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03730012,https://clinicaltrials.gov/study/NCT02892318
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04282668
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT02273102,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02842827,https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT01575691,https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00175812,https://clinicaltrials.gov/study/NCT02842827,https://clinicaltrials.gov/study/NCT02273102,https://clinicaltrials.gov/study/NCT01575691,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT00892190
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	1	Unknown status	https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02261779
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	1	Unknown status	https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02261779
EFO_0000222	acute myeloid leukemia	CHEMBL1643	RIBAVIRIN	Small molecule	Inosine-5'-monophosphate dehydrogenase 1 inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	1	Completed	https://clinicaltrials.gov/study/NCT01056523
EFO_0000222	acute myeloid leukemia	CHEMBL3809489	BEMCENTINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT02488408
EFO_0000222	acute myeloid leukemia	CHEMBL3813873	PEXIDARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01349049
EFO_0000222	acute myeloid leukemia	CHEMBL3813873	PEXIDARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT01349049
EFO_0000222	acute myeloid leukemia	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03390296
EFO_0000222	acute myeloid leukemia	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT02953561,https://clinicaltrials.gov/study/NCT03395873
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454
EFO_0000222	acute myeloid leukemia	CHEMBL1738758	ONVANSERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT03303339
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL3979920	MIVAVOTINIB	Small molecule	Tyrosine-protein kinase SYK inhibitor		SYK	spleen associated tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT04079738,https://clinicaltrials.gov/study/NCT02323113
EFO_0000222	acute myeloid leukemia	CHEMBL3989843	TRANYLCYPROMINE	Small molecule	Monoamine oxidase inhibitor		MAOB	monoamine oxidase B	1	Unknown status	https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02261779
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT02677922
EFO_0000222	acute myeloid leukemia	CHEMBL1742994	BRENTUXIMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01830777
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03728335,https://clinicaltrials.gov/study/NCT05010772,https://clinicaltrials.gov/study/NCT04774393,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05441514
EFO_0000222	acute myeloid leukemia	CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor		CD38	CD38 molecule	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05749276
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Terminated	https://clinicaltrials.gov/study/NCT04092179
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL3989931	ENASIDENIB MESYLATE	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05441514,https://clinicaltrials.gov/study/NCT03728335
EFO_0000222	acute myeloid leukemia	CHEMBL3989931	ENASIDENIB MESYLATE	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Completed	https://clinicaltrials.gov/study/NCT04176393
EFO_0000222	acute myeloid leukemia	CHEMBL3989971	UPROLESELAN	Small molecule	Selectin E antagonist		SELE	selectin E	1	Recruiting	https://clinicaltrials.gov/study/NCT04839341,https://clinicaltrials.gov/study/NCT04964505
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3G	CD3 gamma subunit of T-cell receptor complex	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04158739
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04158739
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3D	CD3 delta subunit of T-cell receptor complex	1	Recruiting	https://clinicaltrials.gov/study/NCT05506956
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3E	CD3 epsilon subunit of T-cell receptor complex	1	Recruiting	https://clinicaltrials.gov/study/NCT05506956
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	1	Recruiting	https://clinicaltrials.gov/study/NCT05506956
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3D	CD3 delta subunit of T-cell receptor complex	1	Terminated	https://clinicaltrials.gov/study/NCT02152956
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02152956
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3E	CD3 epsilon subunit of T-cell receptor complex	1	Terminated	https://clinicaltrials.gov/study/NCT02152956
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01090167,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00727766
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	1	Terminated	https://clinicaltrials.gov/study/NCT02152956
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT00727766,https://clinicaltrials.gov/study/NCT01422603,https://clinicaltrials.gov/study/NCT00529360,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT01090167
EFO_0000222	acute myeloid leukemia	CHEMBL4073443	TOMIVOSERTIB	Small molecule	MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor		MKNK2	MAPK interacting serine/threonine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05744739
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT01160354
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL4091801	APG115	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Recruiting	https://clinicaltrials.gov/study/NCT04358393
EFO_0000222	acute myeloid leukemia	CHEMBL4091801	APG115	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Recruiting	https://clinicaltrials.gov/study/NCT04358393
EFO_0000222	acute myeloid leukemia	CHEMBL421	SULFASALAZINE	Small molecule	Arachidonate 5-lipoxygenase inhibitor		ALOX5	arachidonate 5-lipoxygenase	1	Recruiting	https://clinicaltrials.gov/study/NCT05580861
EFO_0000222	acute myeloid leukemia	CHEMBL421	SULFASALAZINE	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05580861
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT03441555
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Completed	https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT03441555
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT03441555,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT00016016
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	1	Withdrawn	https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Withdrawn	https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL4297423	RO-6870810	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD4	bromodomain containing 4	1	Completed	https://clinicaltrials.gov/study/NCT02308761
EFO_0000222	acute myeloid leukemia	CHEMBL4297522	PEMIGATINIB	Small molecule	Fibroblast growth factor receptor 2 inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04659616
EFO_0000222	acute myeloid leukemia	CHEMBL4297522	PEMIGATINIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Recruiting	https://clinicaltrials.gov/study/NCT04659616
EFO_0000222	acute myeloid leukemia	CHEMBL4297522	PEMIGATINIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04659616
EFO_0000222	acute myeloid leukemia	CHEMBL4297534	GLASDEGIB MALEATE	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05716009,https://clinicaltrials.gov/study/NCT03113643
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	1	Terminated	https://clinicaltrials.gov/study/NCT02270463
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02270463
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL1750	CLOFARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT01065545
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297610	OLUTASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Completed	https://clinicaltrials.gov/study/NCT02719574
EFO_0000222	acute myeloid leukemia	CHEMBL4297880	EVORPACEPT	Protein	Leukocyte surface antigen CD47 inhibitor		CD47	CD47 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04755244
EFO_0000222	acute myeloid leukemia	CHEMBL4297883	IVUXOLIMAB	Antibody	Tumor necrosis factor receptor superfamily member 4 agonist		TNFRSF4	TNF receptor superfamily member 4	1	Completed	https://clinicaltrials.gov/study/NCT03390296
EFO_0000222	acute myeloid leukemia	CHEMBL4297891	CUSATUZUMAB	Antibody	CD70 antigen inhibitor		CD70	CD70 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03030612,https://clinicaltrials.gov/study/NCT04241549
EFO_0000222	acute myeloid leukemia	CHEMBL4297985	MAGROLIMAB	Antibody	Leukocyte surface antigen CD47 inhibitor		CD47	CD47 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04435691
EFO_0000222	acute myeloid leukemia	CHEMBL4297985	MAGROLIMAB	Antibody	Leukocyte surface antigen CD47 inhibitor		CD47	CD47 molecule	1	Completed	https://clinicaltrials.gov/study/NCT02678338
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-W inhibitor		BCL2L2	BCL2 like 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05222984
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-W inhibitor		BCL2L2-PABPN1	BCL2L2-PABPN1 readthrough	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05222984
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-W inhibitor		BCL2L2-PABPN1	BCL2L2-PABPN1 readthrough	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT00315705
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	1	Recruiting	https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05665075
EFO_0000222	acute myeloid leukemia	CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other		CD33	CD33 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT03867682
EFO_0000222	acute myeloid leukemia	CHEMBL2109327	CSL-360	Antibody	Interleukin-3 receptor subunit alpha inhibitor		IL3RA	interleukin 3 receptor subunit alpha 	1	Completed	https://clinicaltrials.gov/study/NCT00401739
EFO_0000222	acute myeloid leukemia	CHEMBL2109480	AHN-12	Antibody	Leukocyte common antigen binding agent		PTPRC	protein tyrosine phosphatase receptor type C	1	Terminated	https://clinicaltrials.gov/study/NCT01207076
EFO_0000222	acute myeloid leukemia	CHEMBL2109498	IPH-2101	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000275546	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	1	Completed	https://clinicaltrials.gov/study/NCT01256073
EFO_0000222	acute myeloid leukemia	CHEMBL2109498	IPH-2101	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000275914	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	1	Completed	https://clinicaltrials.gov/study/NCT01256073
EFO_0000222	acute myeloid leukemia	CHEMBL4594575	SABATOLIMAB	Antibody	Hepatitis A virus cellular receptor 2 inhibitor		HAVCR2	hepatitis A virus cellular receptor 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04623216
EFO_0000222	acute myeloid leukemia	CHEMBL2109498	IPH-2101	Antibody	Killer cell immunoglobulin-like receptor 2DL2 inhibitor		ENSG00000276011	killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2	1	Completed	https://clinicaltrials.gov/study/NCT01256073
EFO_0000222	acute myeloid leukemia	CHEMBL4650278	SNDX-5613	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		KMT2A	lysine methyltransferase 2A	1	Recruiting	https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05360160,https://clinicaltrials.gov/study/NCT06226571
EFO_0000222	acute myeloid leukemia	CHEMBL2109583	F16IL2	Antibody	Tenascin other		TNC	tenascin C	1	Completed	https://clinicaltrials.gov/study/NCT03207191
EFO_0000222	acute myeloid leukemia	CHEMBL2109583	F16IL2	Antibody	Tenascin other		TNC	tenascin C	1	Terminated	https://clinicaltrials.gov/study/NCT02957032
EFO_0000222	acute myeloid leukemia	CHEMBL2141296	IXAZOMIB	Small molecule	26S proteasome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Terminated	https://clinicaltrials.gov/study/NCT04079738
EFO_0000222	acute myeloid leukemia	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05441514
EFO_0000222	acute myeloid leukemia	CHEMBL2347655	FILANESIB	Small molecule	Kinesin-like protein 1 inhibitor		KIF11	kinesin family member 11	1	Completed	https://clinicaltrials.gov/study/NCT00637052
EFO_0000222	acute myeloid leukemia	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT03850535
EFO_0000222	acute myeloid leukemia	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Terminated	https://clinicaltrials.gov/study/NCT03850535
EFO_0000222	acute myeloid leukemia	CHEMBL4650285	TEMUTERKIB	Small molecule	Mitogen-activated protein kinase; ERK1/ERK2 inhibitor		MAPK3	mitogen-activated protein kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT04081259
EFO_0000222	acute myeloid leukemia	CHEMBL4650288	FLYSYN	Antibody	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02789254
EFO_0000222	acute myeloid leukemia	CHEMBL4650295	AMG553	Cell	Tyrosine-protein kinase receptor FLT3 binding agent		FLT3	fms related receptor tyrosine kinase 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT03904069
EFO_0000222	acute myeloid leukemia	CHEMBL4650827	REVUMENIB	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		KMT2A	lysine methyltransferase 2A	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL4650827	REVUMENIB	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		MEN1	menin 1	1	Recruiting	https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT05360160,https://clinicaltrials.gov/study/NCT06222580,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT06226571,https://clinicaltrials.gov/study/NCT05886049
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01222143
EFO_0000222	acute myeloid leukemia	CHEMBL255863	NILOTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Terminated	https://clinicaltrials.gov/study/NCT01222143
EFO_0000222	acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT02960646,https://clinicaltrials.gov/study/NCT02328755
EFO_0000222	acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Recruiting	https://clinicaltrials.gov/study/NCT03467386
EFO_0000222	acute myeloid leukemia	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Terminated	https://clinicaltrials.gov/study/NCT00669890
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT00324220
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 11 inhibitor		HDAC11	histone deacetylase 11	1	Completed	https://clinicaltrials.gov/study/NCT00324220
EFO_0000222	acute myeloid leukemia	CHEMBL272980	MOCETINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT00324220
EFO_0000222	acute myeloid leukemia	CHEMBL479	THIORIDAZINE	Small molecule	Serotonin 2c (5-HT2c) receptor antagonist		HTR2C	5-hydroxytryptamine receptor 2C	1	Completed	https://clinicaltrials.gov/study/NCT02096289
EFO_0000222	acute myeloid leukemia	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL3039543	ULOCUPLUMAB	Antibody	C-X-C chemokine receptor type 4 inhibitor		CXCR4	C-X-C motif chemokine receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT01120457
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04669067,https://clinicaltrials.gov/study/NCT04190550
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT02016729
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Completed	https://clinicaltrials.gov/study/NCT02016729
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Recruiting	https://clinicaltrials.gov/study/NCT03041688
EFO_0000222	acute myeloid leukemia	CHEMBL479	THIORIDAZINE	Small molecule	D2-like dopamine receptor antagonist		DRD3	dopamine receptor D3	1	Completed	https://clinicaltrials.gov/study/NCT02096289
EFO_0000222	acute myeloid leukemia	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT04113616
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03530683,https://clinicaltrials.gov/study/NCT04330820,https://clinicaltrials.gov/study/NCT04435691,https://clinicaltrials.gov/study/NCT04086264,https://clinicaltrials.gov/study/NCT04755244,https://clinicaltrials.gov/study/NCT05222984,https://clinicaltrials.gov/study/NCT04657081,https://clinicaltrials.gov/study/NCT04277442,https://clinicaltrials.gov/study/NCT03874052,https://clinicaltrials.gov/study/NCT06152809,https://clinicaltrials.gov/study/NCT04150887,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04666649,https://clinicaltrials.gov/study/NCT04070768
EFO_0000222	acute myeloid leukemia	CHEMBL4790100	AKN-028	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01573247
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Completed	https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01055483
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Completed	https://clinicaltrials.gov/study/NCT05155709,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT02670044,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT03441555,https://clinicaltrials.gov/study/NCT03672695,https://clinicaltrials.gov/study/NCT03625505,https://clinicaltrials.gov/study/NCT03063944,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT04887857,https://clinicaltrials.gov/study/NCT03735875,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT03390296
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT00840346
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01055483
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Recruiting	https://clinicaltrials.gov/study/NCT03850574,https://clinicaltrials.gov/study/NCT04774393,https://clinicaltrials.gov/study/NCT03844815,https://clinicaltrials.gov/study/NCT05949762,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05597306,https://clinicaltrials.gov/study/NCT05893472,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT05522192,https://clinicaltrials.gov/study/NCT06285890,https://clinicaltrials.gov/study/NCT06150040,https://clinicaltrials.gov/study/NCT03113643,https://clinicaltrials.gov/study/NCT05010772,https://clinicaltrials.gov/study/NCT06449482,https://clinicaltrials.gov/study/NCT05471700,https://clinicaltrials.gov/study/NCT05360160,https://clinicaltrials.gov/study/NCT04964505,https://clinicaltrials.gov/study/NCT05834244,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT05503355,https://clinicaltrials.gov/study/NCT05506332,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT05010122,https://clinicaltrials.gov/study/NCT03867682,https://clinicaltrials.gov/study/NCT05226455,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT05662956,https://clinicaltrials.gov/study/NCT05287568,https://clinicaltrials.gov/study/NCT05263284,https://clinicaltrials.gov/study/NCT03041688,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT06177067
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Completed	https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT01055483
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Completed	https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT00691938
EFO_0000222	acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Withdrawn	https://clinicaltrials.gov/study/NCT03932318,https://clinicaltrials.gov/study/NCT04655391,https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04207190
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04207190
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04207190
EFO_0000222	acute myeloid leukemia	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL3237547	CEDAZURIDINE	Small molecule	Cytidine deaminase inhibitor		CDA	cytidine deaminase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04657081
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL3237547	CEDAZURIDINE	Small molecule	Cytidine deaminase inhibitor		CDA	cytidine deaminase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06484062
EFO_0000222	acute myeloid leukemia	CHEMBL3237547	CEDAZURIDINE	Small molecule	Cytidine deaminase inhibitor		CDA	cytidine deaminase	1	Recruiting	https://clinicaltrials.gov/study/NCT04774393,https://clinicaltrials.gov/study/NCT05010122,https://clinicaltrials.gov/study/NCT05396859,https://clinicaltrials.gov/study/NCT05010772
EFO_0000222	acute myeloid leukemia	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00321581
EFO_0000222	acute myeloid leukemia	CHEMBL3265032	ENTOSPLETINIB	Small molecule	Tyrosine-protein kinase SYK inhibitor		SYK	spleen associated tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT03013998
EFO_0000222	acute myeloid leukemia	CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent		CD19	CD19 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT03896854
EFO_0000222	acute myeloid leukemia	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00321581
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT03730012,https://clinicaltrials.gov/study/NCT02181660,https://clinicaltrials.gov/study/NCT02561455,https://clinicaltrials.gov/study/NCT03625505,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02181660,https://clinicaltrials.gov/study/NCT03730012,https://clinicaltrials.gov/study/NCT03625505,https://clinicaltrials.gov/study/NCT02561455,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT06222580,https://clinicaltrials.gov/study/NCT05010772,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05010122,https://clinicaltrials.gov/study/NCT05546580,https://clinicaltrials.gov/study/NCT05024552
EFO_0000222	acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT04336982,https://clinicaltrials.gov/study/NCT05028751
EFO_0000222	acute myeloid leukemia	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor	Inhibitor	DHFR	dihydrofolate reductase	1	Recruiting	https://clinicaltrials.gov/study/NCT06177067
EFO_0000222	acute myeloid leukemia	CHEMBL3544911	PREXASERTIB	Small molecule	Serine/threonine-protein kinase Chk1 inhibitor		CHEK1	checkpoint kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02649764
EFO_0000222	acute myeloid leukemia	CHEMBL3544932	TAK-901	Small molecule	Serine/threonine-protein kinase Aurora-B inhibitor		AURKB	aurora kinase B	1	Completed	https://clinicaltrials.gov/study/NCT00807677
EFO_0000222	acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02091245
EFO_0000222	acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	1	Completed	https://clinicaltrials.gov/study/NCT02093403,https://clinicaltrials.gov/study/NCT02530476,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT02416908
EFO_0000222	acute myeloid leukemia	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	1	Recruiting	https://clinicaltrials.gov/study/NCT06449482
EFO_0000222	acute myeloid leukemia	CHEMBL3545369	EPACADOSTAT	Small molecule	Indoleamine 2,3-dioxygenase inhibitor		IDO1	indoleamine 2,3-dioxygenase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT03491579
EFO_0000222	acute myeloid leukemia	CHEMBL3545423	AZD-1208	Small molecule	Serine/threonine-protein kinase PIM inhibitor		PIM2	Pim-2 proto-oncogene, serine/threonine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01489722
EFO_0000222	acute myeloid leukemia	CHEMBL3545423	AZD-1208	Small molecule	Serine/threonine-protein kinase PIM inhibitor		PIM1	Pim-1 proto-oncogene, serine/threonine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01489722
EFO_0000222	acute myeloid leukemia	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD4	bromodomain containing 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT02303782
EFO_0000222	acute myeloid leukemia	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD3	bromodomain containing 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT02303782
EFO_0000222	acute myeloid leukemia	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD2	bromodomain containing 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02303782
EFO_0000222	acute myeloid leukemia	CHEMBL3590106	ULIXERTINIB	Small molecule	MAP kinase ERK2 inhibitor		MAPK1	mitogen-activated protein kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02296242
EFO_0000222	acute myeloid leukemia	CHEMBL3590106	ULIXERTINIB	Small molecule	MAP kinase ERK1 inhibitor		MAPK3	mitogen-activated protein kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02296242
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL359164	TROXACITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT00104468
EFO_0000222	acute myeloid leukemia	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3651966	LGH-447	Small molecule	Serine/threonine-protein kinase PIM inhibitor		PIM2	Pim-2 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02078609
EFO_0000222	acute myeloid leukemia	CHEMBL3651966	LGH-447	Small molecule	Serine/threonine-protein kinase PIM inhibitor		PIM1	Pim-1 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02078609
EFO_0000222	acute myeloid leukemia	CHEMBL3651966	LGH-447	Small molecule	Serine/threonine-protein kinase PIM inhibitor		PIM3	Pim-3 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02078609
EFO_0000222	acute myeloid leukemia	CHEMBL3653256	SIREMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT05447663
EFO_0000222	acute myeloid leukemia	CHEMBL3653256	SIREMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT05447663
EFO_0000222	acute myeloid leukemia	CHEMBL3653256	SIREMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT05445154
EFO_0000222	acute myeloid leukemia	CHEMBL3678958	RUSERONTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT02859948
EFO_0000222	acute myeloid leukemia	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT03922477,https://clinicaltrials.gov/study/NCT03154827
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04282668
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04282668
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT00892190,https://clinicaltrials.gov/study/NCT00175812,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01575691,https://clinicaltrials.gov/study/NCT02842827,https://clinicaltrials.gov/study/NCT02273102
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	1	Recruiting	https://clinicaltrials.gov/study/NCT05297123
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05297123
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	1	Recruiting	https://clinicaltrials.gov/study/NCT05297123
EFO_0000222	acute myeloid leukemia	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02261779
EFO_0000222	acute myeloid leukemia	CHEMBL3813873	PEXIDARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01349049
EFO_0000222	acute myeloid leukemia	CHEMBL38434	BREQUINAR	Small molecule	Dihydroorotate dehydrogenase inhibitor		DHODH	dihydroorotate dehydrogenase (quinone)	1	Terminated	https://clinicaltrials.gov/study/NCT03760666
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03530683
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT04580121,https://clinicaltrials.gov/study/NCT02464657
EFO_0000222	acute myeloid leukemia	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Terminated	https://clinicaltrials.gov/study/NCT03465540
EFO_0000222	acute myeloid leukemia	CHEMBL389621	HYDROCORTISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Completed	https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT02270788
EFO_0000222	acute myeloid leukemia	CHEMBL3986824	LANRAPLENIB	Small molecule	Tyrosine-protein kinase SYK inhibitor		SYK	spleen associated tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT05028751
EFO_0000222	acute myeloid leukemia	CHEMBL3989843	TRANYLCYPROMINE	Small molecule	Monoamine oxidase inhibitor		MAOB	monoamine oxidase B	1	Completed	https://clinicaltrials.gov/study/NCT02273102
EFO_0000222	acute myeloid leukemia	CHEMBL3989843	TRANYLCYPROMINE	Small molecule	Monoamine oxidase inhibitor		MAOA	monoamine oxidase A	1	Completed	https://clinicaltrials.gov/study/NCT02273102
EFO_0000222	acute myeloid leukemia	CHEMBL3989843	TRANYLCYPROMINE	Small molecule	Monoamine oxidase inhibitor		MAOA	monoamine oxidase A	1	Unknown status	https://clinicaltrials.gov/study/NCT02261779,https://clinicaltrials.gov/study/NCT02717884
EFO_0000222	acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Completed	https://clinicaltrials.gov/study/NCT03720366,https://clinicaltrials.gov/study/NCT04075747
EFO_0000222	acute myeloid leukemia	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A3	ATPase Na+/K+ transporting subunit alpha 3	1	Terminated	https://clinicaltrials.gov/study/NCT03113071
EFO_0000222	acute myeloid leukemia	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A4	ATPase Na+/K+ transporting subunit alpha 4	1	Terminated	https://clinicaltrials.gov/study/NCT03113071
EFO_0000222	acute myeloid leukemia	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A1	ATPase Na+/K+ transporting subunit alpha 1	1	Terminated	https://clinicaltrials.gov/study/NCT03113071
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04817241
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT02472626
EFO_0000222	acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT02677922
EFO_0000222	acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Recruiting	https://clinicaltrials.gov/study/NCT02074839,https://clinicaltrials.gov/study/NCT04774393,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05010772
EFO_0000222	acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Terminated	https://clinicaltrials.gov/study/NCT02846376
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03874052
EFO_0000222	acute myeloid leukemia	CHEMBL3989971	UPROLESELAN	Small molecule	Selectin E antagonist		SELE	selectin E	1	Completed	https://clinicaltrials.gov/study/NCT02306291
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03874052
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3D	CD3 delta subunit of T-cell receptor complex	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04158739
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04158739
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02152956
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3E	CD3 epsilon subunit of T-cell receptor complex	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04158739
EFO_0000222	acute myeloid leukemia	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02152956
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3G	CD3 gamma subunit of T-cell receptor complex	1	Recruiting	https://clinicaltrials.gov/study/NCT05506956
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05506956
EFO_0000222	acute myeloid leukemia	CHEMBL1795071	RUXOLITINIB PHOSPHATE	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL1829433	AZD-4877	Small molecule	Kinesin-like protein 1 inhibitor		KIF11	kinesin family member 11	1	Terminated	https://clinicaltrials.gov/study/NCT00486265
EFO_0000222	acute myeloid leukemia	CHEMBL18442	PLERIXAFOR	Small molecule	C-X-C chemokine receptor type 4 partial agonist		CXCR4	C-X-C motif chemokine receptor 4	1	Recruiting	https://clinicaltrials.gov/study/NCT06158828
EFO_0000222	acute myeloid leukemia	CHEMBL18442	PLERIXAFOR	Small molecule	C-X-C chemokine receptor type 4 partial agonist		CXCR4	C-X-C motif chemokine receptor 4	1	Terminated	https://clinicaltrials.gov/study/NCT01455025,https://clinicaltrials.gov/study/NCT01160354,https://clinicaltrials.gov/study/NCT01655875,https://clinicaltrials.gov/study/NCT01027923
EFO_0000222	acute myeloid leukemia	CHEMBL1873475	IBRUTINIB	Small molecule	Tyrosine-protein kinase BTK inhibitor		BTK	Bruton tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02635074
EFO_0000222	acute myeloid leukemia	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Recruiting	https://clinicaltrials.gov/study/NCT03132454,https://clinicaltrials.gov/study/NCT05627232
EFO_0000222	acute myeloid leukemia	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT02310243
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Phosphodiesterase 4 inhibitor		PDE4A	phosphodiesterase 4A	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Phosphodiesterase 4 inhibitor		PDE4D	phosphodiesterase 4D	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent		CD3G	CD3 gamma subunit of T-cell receptor complex	1	Terminated	https://clinicaltrials.gov/study/NCT02152956
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Adenosine receptor antagonist		ADORA2A	adenosine A2a receptor	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Phosphodiesterase 4 inhibitor		PDE4B	phosphodiesterase 4B	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL190	THEOPHYLLINE	Small molecule	Adenosine receptor antagonist		ADORA3	adenosine A3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00175812
EFO_0000222	acute myeloid leukemia	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Unknown status	https://clinicaltrials.gov/study/NCT00636922
EFO_0000222	acute myeloid leukemia	CHEMBL1908397	KW-2449	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	1	Terminated	https://clinicaltrials.gov/study/NCT00779480
EFO_0000222	acute myeloid leukemia	CHEMBL1908397	KW-2449	Small molecule	Serine/threonine-protein kinase Aurora-B inhibitor		AURKB	aurora kinase B	1	Terminated	https://clinicaltrials.gov/study/NCT00779480
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Fibroblast growth factor receptor 2 inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase FRK inhibitor		FRK	fyn related Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL4073443	TOMIVOSERTIB	Small molecule	MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor		MKNK1	MAPK interacting serine/threonine kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05744739
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Ephrin type-A receptor 2		EPHA2	EPH receptor A2	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Discoidin domain-containing receptor 2 inhibitor		DDR2	discoidin domain receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT03042689
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Fibroblast growth factor receptor 2 inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Tyrosine-protein kinase FRK inhibitor		FRK	fyn related Src family tyrosine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Ephrin type-A receptor 2		EPHA2	EPH receptor A2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1946170	REGORAFENIB	Small molecule	Discoidin domain-containing receptor 2 inhibitor		DDR2	discoidin domain receptor tyrosine kinase 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06454409
EFO_0000222	acute myeloid leukemia	CHEMBL1983268	ENTRECTINIB	Small molecule	Proto-oncogene tyrosine-protein kinase ROS inhibitor		ROS1	ROS proto-oncogene 1, receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT05396859
EFO_0000222	acute myeloid leukemia	CHEMBL1983268	ENTRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK2	neurotrophic receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05396859
EFO_0000222	acute myeloid leukemia	CHEMBL2043437	GLASDEGIB	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	1	Completed	https://clinicaltrials.gov/study/NCT03390296,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02367456
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL2095206	BOSUTINIB MONOHYDRATE	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655391
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT03484520
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772925
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT00878722
EFO_0000222	acute myeloid leukemia	CHEMBL413	SIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT00861874
EFO_0000222	acute myeloid leukemia	CHEMBL415049	BARASERTIB	Small molecule	Serine/threonine-protein kinase Aurora-B inhibitor		AURKB	aurora kinase B	1	Completed	https://clinicaltrials.gov/study/NCT01019161,https://clinicaltrials.gov/study/NCT00926731,https://clinicaltrials.gov/study/NCT00530699
EFO_0000222	acute myeloid leukemia	CHEMBL4167360	IDH305	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02826642
EFO_0000222	acute myeloid leukemia	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02016729
EFO_0000222	acute myeloid leukemia	CHEMBL4206033	BAY1436032	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Completed	https://clinicaltrials.gov/study/NCT03127735
EFO_0000222	acute myeloid leukemia	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT01236144
EFO_0000222	acute myeloid leukemia	CHEMBL421	SULFASALAZINE	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05580861
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT03441555,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00016016
EFO_0000222	acute myeloid leukemia	CHEMBL2105708	PONATINIB HYDROCHLORIDE	Small molecule	Bcr/Abl fusion protein inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT03441555
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02270788
EFO_0000222	acute myeloid leukemia	CHEMBL2105728	CRENOLANIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02270788
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	1	Completed	https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT03441555,https://clinicaltrials.gov/study/NCT03563560
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Withdrawn	https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04493099
EFO_0000222	acute myeloid leukemia	CHEMBL4297289	BOMEDEMSTAT	Small molecule	Lysine-specific histone demethylase 1 inhibitor		KDM1A	lysine demethylase 1A	1	Completed	https://clinicaltrials.gov/study/NCT02842827
EFO_0000222	acute myeloid leukemia	CHEMBL4297289	BOMEDEMSTAT	Small molecule	Lysine-specific histone demethylase 1 inhibitor		KDM1A	lysine demethylase 1A	1	Recruiting	https://clinicaltrials.gov/study/NCT05597306
EFO_0000222	acute myeloid leukemia	CHEMBL4297423	RO-6870810	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRDT	bromodomain testis associated	1	Completed	https://clinicaltrials.gov/study/NCT02308761
EFO_0000222	acute myeloid leukemia	CHEMBL4297423	RO-6870810	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD3	bromodomain containing 3	1	Completed	https://clinicaltrials.gov/study/NCT02308761
EFO_0000222	acute myeloid leukemia	CHEMBL4297423	RO-6870810	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD2	bromodomain containing 2	1	Completed	https://clinicaltrials.gov/study/NCT02308761
EFO_0000222	acute myeloid leukemia	CHEMBL4297534	GLASDEGIB MALEATE	Small molecule	Smoothened homolog antagonist		SMO	smoothened, frizzled class receptor	1	Completed	https://clinicaltrials.gov/study/NCT03390296
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05716009,https://clinicaltrials.gov/study/NCT03113643
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	1	Recruiting	https://clinicaltrials.gov/study/NCT05716009,https://clinicaltrials.gov/study/NCT03113643
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	1	Terminated	https://clinicaltrials.gov/study/NCT02270463
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT05720988
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT05720988
EFO_0000222	acute myeloid leukemia	CHEMBL4297573	TAGRAXOFUSP	Protein	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	1	Withdrawn	https://clinicaltrials.gov/study/NCT05720988
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02544438
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297599	ASPACYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05503355
EFO_0000222	acute myeloid leukemia	CHEMBL4297763	GTI-2040	Unknown	Ribonucleotide reductase small subunit mRNA antisense inhibitor		RRM2	ribonucleotide reductase regulatory subunit M2	1	Completed	https://clinicaltrials.gov/study/NCT00070551
EFO_0000222	acute myeloid leukemia	CHEMBL4297813	PRI-724	Unknown	CBP/beta catenin inhibitor		CREBBP	CREB binding lysine acetyltransferase 	1	Completed	https://clinicaltrials.gov/study/NCT01606579
EFO_0000222	acute myeloid leukemia	CHEMBL4297813	PRI-724	Unknown	CBP/beta catenin inhibitor		CTNNB1	catenin beta 1	1	Completed	https://clinicaltrials.gov/study/NCT01606579
EFO_0000222	acute myeloid leukemia	CHEMBL4297837	TALACOTUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01632852
EFO_0000222	acute myeloid leukemia	CHEMBL4297837	TALACOTUZUMAB	Antibody	Interleukin-3 receptor subunit alpha binding agent		IL3RA	interleukin 3 receptor subunit alpha 	1	Completed	https://clinicaltrials.gov/study/NCT01632852
EFO_0000222	acute myeloid leukemia	CHEMBL4297871	CAMIDANLUMAB TESIRINE	Antibody drug conjugate	Interleukin-2 receptor alpha chain binding agent		IL2RA	interleukin 2 receptor subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02588092
EFO_0000222	acute myeloid leukemia	CHEMBL4297891	CUSATUZUMAB	Antibody	CD70 antigen inhibitor		CD70	CD70 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04150887
EFO_0000222	acute myeloid leukemia	CHEMBL4297985	MAGROLIMAB	Antibody	Leukocyte surface antigen CD47 inhibitor		CD47	CD47 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT03922477
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-X inhibitor		BCL2L1	BCL2 like 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05222984
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05222984
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-W inhibitor		BCL2L2	BCL2 like 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-X inhibitor		BCL2L1	BCL2 like 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL443684	NAVITOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632708
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632708
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	1	Completed	https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT00315705,https://clinicaltrials.gov/study/NCT01411267
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05665114
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	1	Terminated	https://clinicaltrials.gov/study/NCT02773732,https://clinicaltrials.gov/study/NCT00660036,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT02631252
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00660036,https://clinicaltrials.gov/study/NCT02631252,https://clinicaltrials.gov/study/NCT02773732,https://clinicaltrials.gov/study/NCT01027923
EFO_0000222	acute myeloid leukemia	CHEMBL451887	CARFILZOMIB	Protein	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03530683
EFO_0000222	acute myeloid leukemia	CHEMBL4594253	MIVAVOTINIB CITRATE	Small molecule	Tyrosine-protein kinase SYK inhibitor		SYK	spleen associated tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02323113,https://clinicaltrials.gov/study/NCT04079738
EFO_0000222	acute myeloid leukemia	CHEMBL461101	ELTROMBOPAG	Small molecule	Thrombopoietin receptor agonist		MPL	MPL proto-oncogene, thrombopoietin receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT01113502
EFO_0000222	acute myeloid leukemia	CHEMBL4650278	SNDX-5613	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		MEN1	menin 1	1	Recruiting	https://clinicaltrials.gov/study/NCT06226571,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05360160
EFO_0000222	acute myeloid leukemia	CHEMBL4650283	FF-10101	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT03194685
EFO_0000222	acute myeloid leukemia	CHEMBL4650285	TEMUTERKIB	Small molecule	Mitogen-activated protein kinase; ERK1/ERK2 inhibitor		MAPK1	mitogen-activated protein kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04081259
EFO_0000222	acute myeloid leukemia	CHEMBL4650336	EMVODODSTAT	Small molecule	Dihydroorotate dehydrogenase inhibitor		DHODH	dihydroorotate dehydrogenase (quinone)	1	Terminated	https://clinicaltrials.gov/study/NCT03761069
EFO_0000222	acute myeloid leukemia	CHEMBL4650374	APG-2575	Unknown	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Recruiting	https://clinicaltrials.gov/study/NCT04501120
EFO_0000222	acute myeloid leukemia	CHEMBL4650827	REVUMENIB	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		MEN1	menin 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL4650827	REVUMENIB	Small molecule	Menin/Histone-lysine N-methyltransferase MLL inhibitor		KMT2A	lysine methyltransferase 2A	1	Recruiting	https://clinicaltrials.gov/study/NCT05360160,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT06226571,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT06222580
EFO_0000222	acute myeloid leukemia	CHEMBL479	THIORIDAZINE	Small molecule	D2-like dopamine receptor antagonist		DRD4	dopamine receptor D4	1	Completed	https://clinicaltrials.gov/study/NCT02096289
EFO_0000222	acute myeloid leukemia	CHEMBL479	THIORIDAZINE	Small molecule	Serotonin 2a (5-HT2a) receptor antagonist		HTR2A	5-hydroxytryptamine receptor 2A	1	Completed	https://clinicaltrials.gov/study/NCT02096289
EFO_0000222	acute myeloid leukemia	CHEMBL479	THIORIDAZINE	Small molecule	D2-like dopamine receptor antagonist		DRD2	dopamine receptor D2	1	Completed	https://clinicaltrials.gov/study/NCT02096289
EFO_0000222	acute myeloid leukemia	CHEMBL4802129	BALIXAFORTIDE	Protein	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT01413568
EFO_0000222	acute myeloid leukemia	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	1	Completed	https://clinicaltrials.gov/study/NCT01779843
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Completed	https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT01463046
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Completed	https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT00840346
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Completed	https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT00946647
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Completed	https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT01242774,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT00840346
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT01242774
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT01055483,https://clinicaltrials.gov/study/NCT00691938,https://clinicaltrials.gov/study/NCT00946647,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT00840346,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01242774
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Terminated	https://clinicaltrials.gov/study/NCT02676323
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Unknown status	https://clinicaltrials.gov/study/NCT01451268
EFO_0000222	acute myeloid leukemia	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00321581
EFO_0000222	acute myeloid leukemia	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00321581
EFO_0000222	acute myeloid leukemia	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00321581
EFO_0000222	acute myeloid leukemia	CHEMBL491473	CEDIRANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00321581
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL501867	VINCRISTINE SULFATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03513484
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT01488344
EFO_0000222	acute myeloid leukemia	CHEMBL503	LOVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Terminated	https://clinicaltrials.gov/study/NCT00583102
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00279773
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00783653,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00783653,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00783653
EFO_0000222	acute myeloid leukemia	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT00783653,https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT01020539
EFO_0000222	acute myeloid leukemia	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT01020539
EFO_0000222	acute myeloid leukemia	CHEMBL571209	INDOXIMOD	Small molecule	mTORC1 activator		MLST8	MTOR associated protein MLST8	1	Completed	https://clinicaltrials.gov/study/NCT02835729
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04112589
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04112589
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04112589
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT03723681,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT01236144,https://clinicaltrials.gov/study/NCT02675478,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT03735875,https://clinicaltrials.gov/study/NCT01468467,https://clinicaltrials.gov/study/NCT00462761,https://clinicaltrials.gov/study/NCT01390337
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT01236144,https://clinicaltrials.gov/study/NCT01468467,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT00462761,https://clinicaltrials.gov/study/NCT03723681,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT03735875,https://clinicaltrials.gov/study/NCT02675478
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03735875,https://clinicaltrials.gov/study/NCT01468467,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02675478,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT03723681,https://clinicaltrials.gov/study/NCT01236144,https://clinicaltrials.gov/study/NCT00462761
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT03723681,https://clinicaltrials.gov/study/NCT00462761,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT03735875,https://clinicaltrials.gov/study/NCT01468467,https://clinicaltrials.gov/study/NCT01236144,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02675478,https://clinicaltrials.gov/study/NCT01411267
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04128748
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT04687761
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Recruiting	https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT03661307,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04687761
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT03552029
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT03552029
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT03552029
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT03552029
EFO_0000222	acute myeloid leukemia	CHEMBL576982	QUIZARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT03552029
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632708
EFO_0000222	acute myeloid leukemia	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00819546
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Completed	https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT01130662
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Completed	https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01093573
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT00045942
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00093600
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Completed	https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT01093573
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Completed	https://clinicaltrials.gov/study/NCT00045942,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02078609
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Completed	https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02078609,https://clinicaltrials.gov/study/NCT00977782,https://clinicaltrials.gov/study/NCT01130662,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01093573,https://clinicaltrials.gov/study/NCT00045942
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Completed	https://clinicaltrials.gov/study/NCT01798901
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00042796
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Recruiting	https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04385290
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Recruiting	https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Suspended	https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Terminated	https://clinicaltrials.gov/study/NCT00866281,https://clinicaltrials.gov/study/NCT04496999
EFO_0000330	childhood acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000330	childhood acute myeloid leukemia	CHEMBL225071	RALTITREXED	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Completed	https://clinicaltrials.gov/study/NCT00003528
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Terminated	https://clinicaltrials.gov/study/NCT00866281,https://clinicaltrials.gov/study/NCT04496999
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT05756777,https://clinicaltrials.gov/study/NCT04240002,https://clinicaltrials.gov/study/NCT05520567
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00866281,https://clinicaltrials.gov/study/NCT04496999
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3301622	GILTERITINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT05520567,https://clinicaltrials.gov/study/NCT05756777,https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3989908	ENASIDENIB	Small molecule	Isocitrate dehydrogenase [NADP], mitochondrial inhibitor		IDH2	isocitrate dehydrogenase (NADP(+)) 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05756777
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000330	childhood acute myeloid leukemia	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00217412
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Terminated	https://clinicaltrials.gov/study/NCT00866281,https://clinicaltrials.gov/study/NCT04496999
EFO_0000330	childhood acute myeloid leukemia	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00217412
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Terminated	https://clinicaltrials.gov/study/NCT00866281,https://clinicaltrials.gov/study/NCT04496999
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Terminated	https://clinicaltrials.gov/study/NCT04496999,https://clinicaltrials.gov/study/NCT00866281
EFO_0000330	childhood acute myeloid leukemia	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT00217412
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000222	acute myeloid leukemia	CHEMBL608533	MIDOSTAURIN	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT00217412
EFO_0000330	childhood acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT00217412
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3	1	Completed	https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA1	gamma-aminobutyric acid type A receptor subunit alpha1	1	Completed	https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA2	gamma-aminobutyric acid type A receptor subunit alpha2	1	Completed	https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG3	gamma-aminobutyric acid type A receptor subunit gamma3	1	Completed	https://clinicaltrials.gov/study/NCT02014558
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG2	gamma-aminobutyric acid type A receptor subunit gamma2	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG3	gamma-aminobutyric acid type A receptor subunit gamma3	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA5	gamma-aminobutyric acid type A receptor subunit alpha5	1	Withdrawn	https://clinicaltrials.gov/study/NCT03760445
EFO_0000222	acute myeloid leukemia	CHEMBL657	DIPHENHYDRAMINE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	1	Completed	https://clinicaltrials.gov/study/NCT04580121
EFO_0000222	acute myeloid leukemia	CHEMBL68117	VOSAROXIN	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	1	Completed	https://clinicaltrials.gov/study/NCT00246662
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT03330821,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT04158739
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT03330821
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT03330821
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT03330821,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT02632708
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT03330821,https://clinicaltrials.gov/study/NCT04190550,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT02310321
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03844997,https://clinicaltrials.gov/study/NCT04112589,https://clinicaltrials.gov/study/NCT02310321,https://clinicaltrials.gov/study/NCT03330821,https://clinicaltrials.gov/study/NCT04817241,https://clinicaltrials.gov/study/NCT04158739,https://clinicaltrials.gov/study/NCT02632708,https://clinicaltrials.gov/study/NCT04190550
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT01321346
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT02909972
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT00081822,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT02070458
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00542971,https://clinicaltrials.gov/study/NCT00569010,https://clinicaltrials.gov/study/NCT01390337,https://clinicaltrials.gov/study/NCT02649764,https://clinicaltrials.gov/study/NCT02921061,https://clinicaltrials.gov/study/NCT00875693,https://clinicaltrials.gov/study/NCT02909972,https://clinicaltrials.gov/study/NCT02971397,https://clinicaltrials.gov/study/NCT02326584,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT01635296,https://clinicaltrials.gov/study/NCT00995332,https://clinicaltrials.gov/study/NCT03661515,https://clinicaltrials.gov/study/NCT02046122,https://clinicaltrials.gov/study/NCT01729845,https://clinicaltrials.gov/study/NCT02779283,https://clinicaltrials.gov/study/NCT02626338,https://clinicaltrials.gov/study/NCT03531918,https://clinicaltrials.gov/study/NCT01768897,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02573363,https://clinicaltrials.gov/study/NCT02403310,https://clinicaltrials.gov/study/NCT03563560,https://clinicaltrials.gov/study/NCT02306291,https://clinicaltrials.gov/study/NCT02236013,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT02719574,https://clinicaltrials.gov/study/NCT00512252,https://clinicaltrials.gov/study/NCT01861002,https://clinicaltrials.gov/study/NCT02416908,https://clinicaltrials.gov/study/NCT03303339,https://clinicaltrials.gov/study/NCT02038777,https://clinicaltrials.gov/study/NCT02287233,https://clinicaltrials.gov/study/NCT02270788,https://clinicaltrials.gov/study/NCT01641250,https://clinicaltrials.gov/study/NCT01690507,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT00850382,https://clinicaltrials.gov/study/NCT01779843,https://clinicaltrials.gov/study/NCT01249430,https://clinicaltrials.gov/study/NCT02575963,https://clinicaltrials.gov/study/NCT02464657,https://clinicaltrials.gov/study/NCT00780104,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT02070458,https://clinicaltrials.gov/study/NCT02835729,https://clinicaltrials.gov/study/NCT01463046,https://clinicaltrials.gov/study/NCT03194932,https://clinicaltrials.gov/study/NCT02582359,https://clinicaltrials.gov/study/NCT01435343,https://clinicaltrials.gov/study/NCT01161550,https://clinicaltrials.gov/study/NCT03298984,https://clinicaltrials.gov/study/NCT00093600,https://clinicaltrials.gov/study/NCT03441048,https://clinicaltrials.gov/study/NCT01830777,https://clinicaltrials.gov/study/NCT01787474,https://clinicaltrials.gov/study/NCT03393611,https://clinicaltrials.gov/study/NCT01056523,https://clinicaltrials.gov/study/NCT02891278,https://clinicaltrials.gov/study/NCT02834390,https://clinicaltrials.gov/study/NCT04075747,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT00906945,https://clinicaltrials.gov/study/NCT00070551,https://clinicaltrials.gov/study/NCT02400281,https://clinicaltrials.gov/study/NCT00541866,https://clinicaltrials.gov/study/NCT04038437,https://clinicaltrials.gov/study/NCT01321346,https://clinicaltrials.gov/study/NCT01411267,https://clinicaltrials.gov/study/NCT01773408,https://clinicaltrials.gov/study/NCT00081822
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT06007911,https://clinicaltrials.gov/study/NCT05100303
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05100303,https://clinicaltrials.gov/study/NCT06313437,https://clinicaltrials.gov/study/NCT06007911
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT05317403
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT05317403
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT04990102
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT04982354
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT05627232,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT03013998
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05659992,https://clinicaltrials.gov/study/NCT04659616,https://clinicaltrials.gov/study/NCT04049539,https://clinicaltrials.gov/study/NCT04990102,https://clinicaltrials.gov/study/NCT05886049,https://clinicaltrials.gov/study/NCT05024552,https://clinicaltrials.gov/study/NCT05319587,https://clinicaltrials.gov/study/NCT05665114,https://clinicaltrials.gov/study/NCT04220684,https://clinicaltrials.gov/study/NCT05558124,https://clinicaltrials.gov/study/NCT03214562,https://clinicaltrials.gov/study/NCT06177067,https://clinicaltrials.gov/study/NCT05601466,https://clinicaltrials.gov/study/NCT05453903,https://clinicaltrials.gov/study/NCT03013998,https://clinicaltrials.gov/study/NCT04385290,https://clinicaltrials.gov/study/NCT04982354,https://clinicaltrials.gov/study/NCT04128748,https://clinicaltrials.gov/study/NCT03793478,https://clinicaltrials.gov/study/NCT05665075,https://clinicaltrials.gov/study/NCT03709758,https://clinicaltrials.gov/study/NCT05317403,https://clinicaltrials.gov/study/NCT04687761,https://clinicaltrials.gov/study/NCT05627232
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03983824,https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03983824,https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03983824,https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03983824,https://clinicaltrials.gov/study/NCT03900949
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03900949,https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03900949,https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Suspended	https://clinicaltrials.gov/study/NCT03900949,https://clinicaltrials.gov/study/NCT03983824
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT01027923
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT04956042
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT00480987
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT04196010
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT01853228,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT01265199
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT04196010,https://clinicaltrials.gov/study/NCT03724084,https://clinicaltrials.gov/study/NCT04956042,https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT02109627,https://clinicaltrials.gov/study/NCT02875093,https://clinicaltrials.gov/study/NCT01656252,https://clinicaltrials.gov/study/NCT03904251,https://clinicaltrials.gov/study/NCT02676323,https://clinicaltrials.gov/study/NCT01027923,https://clinicaltrials.gov/study/NCT03634228,https://clinicaltrials.gov/study/NCT00480987,https://clinicaltrials.gov/study/NCT03135028,https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT02343939,https://clinicaltrials.gov/study/NCT02412475,https://clinicaltrials.gov/study/NCT01187810,https://clinicaltrials.gov/study/NCT01701323,https://clinicaltrials.gov/study/NCT01265199,https://clinicaltrials.gov/study/NCT02440568,https://clinicaltrials.gov/study/NCT02954653,https://clinicaltrials.gov/study/NCT03878927,https://clinicaltrials.gov/study/NCT05712278,https://clinicaltrials.gov/study/NCT02635074,https://clinicaltrials.gov/study/NCT00907517,https://clinicaltrials.gov/study/NCT02957032,https://clinicaltrials.gov/study/NCT03850535,https://clinicaltrials.gov/study/NCT00583102,https://clinicaltrials.gov/study/NCT01853228
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT03031262
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT02140606
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT01534702
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT03031249,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT02140606
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Unknown status	https://clinicaltrials.gov/study/NCT03031262,https://clinicaltrials.gov/study/NCT02576301,https://clinicaltrials.gov/study/NCT02413021,https://clinicaltrials.gov/study/NCT01534702,https://clinicaltrials.gov/study/NCT02488408,https://clinicaltrials.gov/study/NCT02886559,https://clinicaltrials.gov/study/NCT02717884,https://clinicaltrials.gov/study/NCT02140606,https://clinicaltrials.gov/study/NCT03031249
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT02905994,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT03491579
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT02905994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT03491579,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02905994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT02905994,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT03491579
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02680951,https://clinicaltrials.gov/study/NCT05330377,https://clinicaltrials.gov/study/NCT02472626,https://clinicaltrials.gov/study/NCT02905994,https://clinicaltrials.gov/study/NCT03760445,https://clinicaltrials.gov/study/NCT03444649,https://clinicaltrials.gov/study/NCT01478074,https://clinicaltrials.gov/study/NCT03491579
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02312102
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02312102
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02312102
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02312102
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	1	Completed	https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT01016600,https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT01433965,https://clinicaltrials.gov/study/NCT01578954
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	1	Completed	https://clinicaltrials.gov/study/NCT01246622,https://clinicaltrials.gov/study/NCT01578954,https://clinicaltrials.gov/study/NCT00831766,https://clinicaltrials.gov/study/NCT01016600,https://clinicaltrials.gov/study/NCT01681537,https://clinicaltrials.gov/study/NCT01433965
EFO_0000222	acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	1	Terminated	https://clinicaltrials.gov/study/NCT02255162,https://clinicaltrials.gov/study/NCT00923234,https://clinicaltrials.gov/study/NCT02038153,https://clinicaltrials.gov/study/NCT00839059
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT05101551
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000222	acute myeloid leukemia	CHEMBL90555	VINCRISTINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT02779283
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Completed	https://clinicaltrials.gov/study/NCT01798901
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00042796
EFO_0000222	acute myeloid leukemia	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00088231
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT01534260,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT00479232
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT03263936,https://clinicaltrials.gov/study/NCT00875745,https://clinicaltrials.gov/study/NCT00479232,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT01534260
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Recruiting	https://clinicaltrials.gov/study/NCT05317403
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05317403
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT05317403
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT02412475
EFO_0000222	acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02412475
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05520567
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05520567
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor		CD38	CD38 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03537599
EFO_0000330	childhood acute myeloid leukemia	CHEMBL1976040	ADAVOSERTIB	Small molecule	Serine/threonine-protein kinase WEE1 inhibitor		WEE1	WEE1 G2 checkpoint kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Recruiting	https://clinicaltrials.gov/study/NCT05520567
EFO_0000330	childhood acute myeloid leukemia	CHEMBL3989958	IVOSIDENIB	Small molecule	Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor		IDH1	isocitrate dehydrogenase (NADP(+)) 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05756777
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02642965
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04240002
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Withdrawn	https://clinicaltrials.gov/study/NCT02791919
EFO_0000330	childhood acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT00217412
EFO_0000330	childhood acute myeloid leukemia	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT00217412
EFO_1001934	adult acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02204085
EFO_1001934	adult acute myeloid leukemia	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02204085
EFO_1001934	adult acute myeloid leukemia	CHEMBL3545264	LY-2874455	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT03125239
EFO_1001934	adult acute myeloid leukemia	CHEMBL3545264	LY-2874455	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT03125239
EFO_1001934	adult acute myeloid leukemia	CHEMBL3545307	MERESTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT03125239
EFO_1001934	adult acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	1	Completed	https://clinicaltrials.gov/study/NCT00890929
EFO_1001934	adult acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	1	Completed	https://clinicaltrials.gov/study/NCT00890929
EFO_1001934	adult acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Completed	https://clinicaltrials.gov/study/NCT00890929
EFO_1001934	adult acute myeloid leukemia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Completed	https://clinicaltrials.gov/study/NCT00890929
EFO_1001934	adult acute myeloid leukemia	CHEMBL3545264	LY-2874455	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT03125239
EFO_1001934	adult acute myeloid leukemia	CHEMBL3545264	LY-2874455	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT03125239
EFO_1001934	adult acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	1	Completed	https://clinicaltrials.gov/study/NCT00890929
EFO_1001934	adult acute myeloid leukemia	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	1	Completed	https://clinicaltrials.gov/study/NCT00890929
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00042796
EFO_1001945	childhood acute myeloid leukemia with maturation	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00042796
MONDO_0019456	acute myeloid leukemia with multilineage dysplasia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Completed	https://clinicaltrials.gov/study/NCT03047993
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314,https://clinicaltrials.gov/study/NCT03009240
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Completed	https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02093403,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT01798901,https://clinicaltrials.gov/study/NCT00703300,https://clinicaltrials.gov/study/NCT02316964
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03041688
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT02316964
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT02044796
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		UBA3	ubiquitin like modifier activating enzyme 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03009240
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1231160	PEVONEDISTAT	Small molecule	NEDD8 activating enzyme inhibitor		NAE1	NEDD8 activating enzyme E1 subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03009240
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02299518
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1563	DAUNORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02323607
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT02323607
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199,https://clinicaltrials.gov/study/NCT03558607
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL269732	TACROLIMUS ANHYDROUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Recruiting	https://clinicaltrials.gov/study/NCT03041688
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Recruiting	https://clinicaltrials.gov/study/NCT03041688
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Terminated	https://clinicaltrials.gov/study/NCT04113616
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	1	Completed	https://clinicaltrials.gov/study/NCT02485535,https://clinicaltrials.gov/study/NCT02093403,https://clinicaltrials.gov/study/NCT02299518
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRDT	bromodomain testis associated	1	Terminated	https://clinicaltrials.gov/study/NCT02698189
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD4	bromodomain containing 4	1	Terminated	https://clinicaltrials.gov/study/NCT02698189
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD2	bromodomain containing 2	1	Terminated	https://clinicaltrials.gov/study/NCT02698189
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT00016016
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00016016
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	1	Completed	https://clinicaltrials.gov/study/NCT00016016
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00016016
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Completed	https://clinicaltrials.gov/study/NCT00016016
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Serine/threonine-protein kinase Chk1 inhibitor		CHEK1	checkpoint kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04915612,https://clinicaltrials.gov/study/NCT04848974
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04915612,https://clinicaltrials.gov/study/NCT04848974
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04915612,https://clinicaltrials.gov/study/NCT04848974
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT00039117
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02044796
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02323607
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT01130506
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT02299518
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01876953,https://clinicaltrials.gov/study/NCT04113616
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT01130506
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT01130506
MONDO_0019456	acute myeloid leukemia with multilineage dysplasia	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Completed	https://clinicaltrials.gov/study/NCT03047993
MONDO_0019456	acute myeloid leukemia with multilineage dysplasia	CHEMBL3639788	TELAGLENASTAT	Small molecule	Glutaminase kidney isoform, mitochondrial inhibitor		GLS	glutaminase	1	Completed	https://clinicaltrials.gov/study/NCT03047993
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1117	IDARUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03009240,https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Completed	https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT02316964,https://clinicaltrials.gov/study/NCT00703300,https://clinicaltrials.gov/study/NCT01798901,https://clinicaltrials.gov/study/NCT02093403,https://clinicaltrials.gov/study/NCT01130506
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT03041688
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT00042796
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00042796,https://clinicaltrials.gov/study/NCT04113616
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT02316964
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Terminated	https://clinicaltrials.gov/study/NCT01640301
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent		CD33	CD33 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent		MS4A1	membrane spanning 4-domains A1	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1456	MYCOPHENOLATE MOFETIL	Small molecule	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor		IMPDH2	inosine monophosphate dehydrogenase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03558607,https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL18442	PLERIXAFOR	Small molecule	C-X-C chemokine receptor type 4 partial agonist		CXCR4	C-X-C motif chemokine receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT01319864
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1976040	ADAVOSERTIB	Small molecule	Serine/threonine-protein kinase WEE1 inhibitor		WEE1	WEE1 G2 checkpoint kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL2035187	PACRITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02323607
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL2035187	PACRITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02323607
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL2109229	OBLIMERSEN SODIUM	Oligonucleotide	Bcl-2 mRNA antisense inhibitor		BCL2	BCL2 apoptosis regulator	1	Completed	https://clinicaltrials.gov/study/NCT00039117
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3125702	NAVTEMADLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT04113616
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Recruiting	https://clinicaltrials.gov/study/NCT03041688
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01861314
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Completed	https://clinicaltrials.gov/study/NCT00703300
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD3	bromodomain containing 3	1	Terminated	https://clinicaltrials.gov/study/NCT02698189
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL3989971	UPROLESELAN	Small molecule	Selectin E antagonist		SELE	selectin E	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04848974
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02381548
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00016016
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	1	Completed	https://clinicaltrials.gov/study/NCT02299518
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02299518
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	3-phosphoinositide dependent protein kinase-1 inhibitor		PDPK1	3-phosphoinositide dependent protein kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Completed	https://clinicaltrials.gov/study/NCT00301938
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT00016016
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04848974,https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04848974,https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04848974,https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04915612,https://clinicaltrials.gov/study/NCT04848974
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04848974,https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04915612,https://clinicaltrials.gov/study/NCT04848974
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04848974,https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04848974,https://clinicaltrials.gov/study/NCT04915612
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT02299518
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02323607,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02642965
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01130506,https://clinicaltrials.gov/study/NCT02642965,https://clinicaltrials.gov/study/NCT00016016,https://clinicaltrials.gov/study/NCT02044796,https://clinicaltrials.gov/study/NCT00039117,https://clinicaltrials.gov/study/NCT02299518,https://clinicaltrials.gov/study/NCT02323607
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT03878199
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01876953,https://clinicaltrials.gov/study/NCT04113616
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT04113616,https://clinicaltrials.gov/study/NCT01876953
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT01876953,https://clinicaltrials.gov/study/NCT04113616
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL848	LENALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	1	Unknown status	https://clinicaltrials.gov/study/NCT01619761
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT01130506
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT01130506
EFO_0000222	acute myeloid leukemia	CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody drug conjugate	Myeloid cell surface antigen CD33 binding agent		CD33	CD33 molecule	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03291353
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
EFO_0000222	acute myeloid leukemia	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03568994
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	0.5	Completed	https://clinicaltrials.gov/study/NCT04518345
MONDO_0019457	therapy related acute myeloid leukemia and myelodysplastic syndrome	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	0.5	Completed	https://clinicaltrials.gov/study/NCT04518345